<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/qjV9X6eAITVoewO3kT-cv56AHTi5rVUefEcdoYQK7RYqU_PH8TZhb8KIPnvyWGD-3f7h0Jx37H5F4dTXbF2aQg=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"colorectal-cancer;translational-research","webtrendsContentCategory":null,"webtrendsContentCollection":"Cancer research","webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-022-01886-0"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Andrea Sartore-Bianchi","Filippo Pietrantonio","Sara Lonardi","Benedetta Mussolin","Francesco Rua","Giovanni Crisafulli","Alice Bartolini","Elisabetta Fenocchio","Alessio Amatu","Paolo Manca","Francesca Bergamo","Federica Tosi","Gianluca Mauri","Margherita Ambrosini","Francesca Daniel","Valter Torri","Angelo Vanzulli","Daniele Regge","Giovanni Cappello","Caterina Marchi√≤","Enrico Berrino","Anna Sapino","Silvia Marsoni","Salvatore Siena","Alberto Bardelli"],"publishedAt":1659312000,"publishedAtString":"2022-08-01","title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Colorectal cancer,Translational research"},"journal":{"pcode":"nm","title":"nature medicine","volume":"28","issue":"8","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":{"id":"cbhjcefecb"}},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","description":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: \n                NCT03227926\n                \n              ; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue-RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting. In a phase 2 trial, monitoring tumor resistance mutations in blood using liquid biopsies allowed rationally guided subsequent therapy with anti-EGFR antibodies in patients with colorectal cancer.","datePublished":"2022-08-01T00:00:00Z","dateModified":"2022-08-01T00:00:00Z","pageStart":"1612","pageEnd":"1618","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-022-01886-0","keywords":["Colorectal cancer","Translational research","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig4_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"28","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Andrea Sartore-Bianchi","url":"http://orcid.org/0000-0003-0780-0409","affiliation":[{"name":"Universit√† degli Studi di Milano (La Statale)","address":{"name":"Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"Grande Ospedale Metropolitano Niguarda","address":{"name":"Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Filippo Pietrantonio","url":"http://orcid.org/0000-0002-8530-8420","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori","address":{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sara Lonardi","url":"http://orcid.org/0000-0002-7593-8138","affiliation":[{"name":"Veneto Institute of Oncology IOV-IRCCS Padua","address":{"name":"Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Benedetta Mussolin","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Francesco Rua","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Giovanni Crisafulli","url":"http://orcid.org/0000-0002-5511-1555","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Turin","address":{"name":"Department of Oncology, University of Turin, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Alice Bartolini","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Elisabetta Fenocchio","url":"http://orcid.org/0000-0001-6679-0955","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Alessio Amatu","url":"http://orcid.org/0000-0001-5396-3378","affiliation":[{"name":"Grande Ospedale Metropolitano Niguarda","address":{"name":"Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Paolo Manca","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori","address":{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Francesca Bergamo","affiliation":[{"name":"Veneto Institute of Oncology IOV-IRCCS Padua","address":{"name":"Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Federica Tosi","affiliation":[{"name":"Grande Ospedale Metropolitano Niguarda","address":{"name":"Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Gianluca Mauri","url":"http://orcid.org/0000-0002-7646-0973","affiliation":[{"name":"Universit√† degli Studi di Milano (La Statale)","address":{"name":"Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"IFOM, FIRC Institute of Molecular Oncology","address":{"name":"IFOM, FIRC Institute of Molecular Oncology, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Margherita Ambrosini","url":"http://orcid.org/0000-0003-4131-2409","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori","address":{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Francesca Daniel","affiliation":[{"name":"Veneto Institute of Oncology IOV-IRCCS Padua","address":{"name":"Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Valter Torri","affiliation":[{"name":"Mario Negri Institute for Pharmacological Research-IRCCS","address":{"name":"Mario Negri Institute for Pharmacological Research-IRCCS, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Angelo Vanzulli","affiliation":[{"name":"Universit√† degli Studi di Milano (La Statale)","address":{"name":"Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"Grande Ospedale Metropolitano Niguarda","address":{"name":"Department of Services, Grande Ospedale Metropolitano Niguarda, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Daniele Regge","affiliation":[{"name":"University of Turin","address":{"name":"Department of Surgical Sciences, University of Turin, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS","address":{"name":"Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Giovanni Cappello","affiliation":[{"name":"Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS","address":{"name":"Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Caterina Marchi√≤","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Turin","address":{"name":"Department of Medical Sciences, University of Turin, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Enrico Berrino","url":"http://orcid.org/0000-0001-6728-5619","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Turin","address":{"name":"Department of Medical Sciences, University of Turin, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Anna Sapino","url":"http://orcid.org/0000-0003-3542-9571","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Turin","address":{"name":"Department of Medical Sciences, University of Turin, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Silvia Marsoni","affiliation":[{"name":"IFOM, FIRC Institute of Molecular Oncology","address":{"name":"IFOM, FIRC Institute of Molecular Oncology, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Salvatore Siena","url":"http://orcid.org/0000-0002-2681-2846","affiliation":[{"name":"Universit√† degli Studi di Milano (La Statale)","address":{"name":"Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"Grande Ospedale Metropolitano Niguarda","address":{"name":"Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Alberto Bardelli","url":"http://orcid.org/0000-0003-1647-5070","affiliation":[{"name":"FPO-IRCCS","address":{"name":"Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Turin","address":{"name":"Department of Oncology, University of Turin, Turin, Italy","@type":"PostalAddress"},"@type":"Organization"}],"email":"alberto.bardelli@unito.it","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-022-01886-0">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial">
    <meta name="dc.source" content="Nature Medicine 2022 28:8">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2022-08-01">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2022 The Author(s)">
    <meta name="dc.rights" content="2022 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: NCT03227926 ; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue-RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting. In a phase 2 trial, monitoring tumor resistance mutations in blood using liquid biopsies allowed rationally guided subsequent therapy with anti-EGFR antibodies in patients with colorectal cancer.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2022-08-01">
    <meta name="prism.volume" content="28">
    <meta name="prism.number" content="8">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="1612">
    <meta name="prism.endingPage" content="1618">
    <meta name="prism.copyright" content="2022 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-022-01886-0">
    <meta name="prism.doi" content="doi:10.1038/s41591-022-01886-0">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-022-01886-0.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-022-01886-0">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial">
    <meta name="citation_volume" content="28">
    <meta name="citation_issue" content="8">
    <meta name="citation_publication_date" content="2022/08">
    <meta name="citation_online_date" content="2022/08/01">
    <meta name="citation_firstpage" content="1612">
    <meta name="citation_lastpage" content="1618">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-022-01886-0">
    <meta name="DOI" content="10.1038/s41591-022-01886-0">
    <meta name="size" content="187556">
    <meta name="citation_doi" content="10.1038/s41591-022-01886-0">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-022-01886-0&amp;api_key=">
    <meta name="description" content="Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: NCT03227926 ; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue-RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting. In a phase 2 trial, monitoring tumor resistance mutations in blood using liquid biopsies allowed rationally guided subsequent therapy with anti-EGFR antibodies in patients with colorectal cancer.">
    <meta name="dc.creator" content="Sartore-Bianchi, Andrea">
    <meta name="dc.creator" content="Pietrantonio, Filippo">
    <meta name="dc.creator" content="Lonardi, Sara">
    <meta name="dc.creator" content="Mussolin, Benedetta">
    <meta name="dc.creator" content="Rua, Francesco">
    <meta name="dc.creator" content="Crisafulli, Giovanni">
    <meta name="dc.creator" content="Bartolini, Alice">
    <meta name="dc.creator" content="Fenocchio, Elisabetta">
    <meta name="dc.creator" content="Amatu, Alessio">
    <meta name="dc.creator" content="Manca, Paolo">
    <meta name="dc.creator" content="Bergamo, Francesca">
    <meta name="dc.creator" content="Tosi, Federica">
    <meta name="dc.creator" content="Mauri, Gianluca">
    <meta name="dc.creator" content="Ambrosini, Margherita">
    <meta name="dc.creator" content="Daniel, Francesca">
    <meta name="dc.creator" content="Torri, Valter">
    <meta name="dc.creator" content="Vanzulli, Angelo">
    <meta name="dc.creator" content="Regge, Daniele">
    <meta name="dc.creator" content="Cappello, Giovanni">
    <meta name="dc.creator" content="Marchi√≤, Caterina">
    <meta name="dc.creator" content="Berrino, Enrico">
    <meta name="dc.creator" content="Sapino, Anna">
    <meta name="dc.creator" content="Marsoni, Silvia">
    <meta name="dc.creator" content="Siena, Salvatore">
    <meta name="dc.creator" content="Bardelli, Alberto">
    <meta name="dc.subject" content="Colorectal cancer">
    <meta name="dc.subject" content="Translational research">
    <meta name="citation_reference" content="citation_journal_title=CA Cancer J. Clin.; citation_title=Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries; citation_author=H Sung; citation_volume=71; citation_publication_date=2021; citation_pages=209-249; citation_doi=10.3322/caac.21660; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=CA Cancer J. Clin.; citation_title=Cancer statistics, 2021; citation_author=RL Siegel, KD Miller, HE Fuchs, A Jemal; citation_volume=71; citation_publication_date=2021; citation_pages=7-33; citation_doi=10.3322/caac.21654; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Clin. Oncol.; citation_title=Precision oncology in metastatic colorectal cancer‚Äîfrom biology to medicine; citation_author=F Nicolantonio; citation_volume=18; citation_publication_date=2021; citation_pages=506-525; citation_doi=10.1038/s41571-021-00495-z; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=Mol. Oncol.; citation_title=Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients; citation_author=G Siravegna, A Bardelli; citation_volume=10; citation_publication_date=2016; citation_pages=475-480; citation_doi=10.1016/j.molonc.2015.12.005; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer; citation_author=S Misale; citation_volume=486; citation_publication_date=2012; citation_pages=532-536; citation_doi=10.1038/nature11156; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res; citation_title=Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer; citation_author=S Arena; citation_volume=21; citation_publication_date=2015; citation_pages=2157-2166; citation_doi=10.1158/1078-0432.CCR-14-2821; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer; citation_author=F Nicolantonio; citation_volume=26; citation_publication_date=2008; citation_pages=5705-5712; citation_doi=10.1200/JCO.2008.18.0786; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=JAMA Oncol.; citation_title=Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA Analyses: a phase 2 randomized clinical trial; citation_author=C Montagut; citation_volume=4; citation_publication_date=2018; citation_pages=e175245; citation_doi=10.1001/jamaoncol.2017.5245; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients; citation_author=G Siravegna; citation_volume=21; citation_publication_date=2015; citation_pages=795-801; citation_doi=10.1038/nm.3870; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment; citation_author=MP Morelli; citation_volume=26; citation_publication_date=2015; citation_pages=731-736; citation_doi=10.1093/annonc/mdv005; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge; citation_author=CM Parseghian; citation_volume=30; citation_publication_date=2019; citation_pages=243-249; citation_doi=10.1093/annonc/mdy509; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer; citation_author=S Siena; citation_volume=29; citation_publication_date=2018; citation_pages=119-126; citation_doi=10.1093/annonc/mdx504; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Clin. Oncol.; citation_title=Integrating liquid biopsies into the management of cancer; citation_author=G Siravegna, S Marsoni, S Siena, A Bardelli; citation_volume=14; citation_publication_date=2017; citation_pages=531-548; citation_doi=10.1038/nrclinonc.2017.14; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Randomized trial of TAS-102 for refractory metastatic colorectal cancer; citation_author=RJ Mayer; citation_volume=372; citation_publication_date=2015; citation_pages=1909-1919; citation_doi=10.1056/NEJMoa1414325; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial; citation_author=A Grothey; citation_volume=381; citation_publication_date=2013; citation_pages=303-312; citation_doi=10.1016/S0140-6736(12)61900-X; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=Cancer Cell; citation_title=Breaking barriers in HER2+ cancers; citation_author=S Siena, S Marsoni, A Sartore-Bianchi; citation_volume=38; citation_publication_date=2020; citation_pages=317-319; citation_doi=10.1016/j.ccell.2020.07.012; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer; citation_author=A Amatu; citation_volume=30; citation_publication_date=2019; citation_pages=viii5-viii15; citation_doi=10.1093/annonc/mdz383; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=J. Natl Compr. Cancer Netw.; citation_title=Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology; citation_author=AB Benson; citation_volume=19; citation_publication_date=2021; citation_pages=329-359; citation_doi=10.6004/jnccn.2021.0012; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS; citation_author=T Yoshino; citation_volume=29; citation_publication_date=2018; citation_pages=44-70; citation_doi=10.1093/annonc/mdx738; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=Cancer Treat. Rev.; citation_title=Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies; citation_author=G Mauri; citation_volume=73; citation_publication_date=2019; citation_pages=41-53; citation_doi=10.1016/j.ctrv.2018.12.006; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=Cancer Treat. Rev.; citation_title=Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities; citation_author=G Mauri; citation_volume=91; citation_publication_date=2020; citation_pages=102112; citation_doi=10.1016/j.ctrv.2020.102112; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=JAMA Oncol.; citation_title=Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.; citation_author=C Cremolini; citation_volume=5; citation_publication_date=2019; citation_pages=343-350; citation_doi=10.1001/jamaoncol.2018.5080; citation_id=CR22">
    <meta name="citation_reference" content="citation_journal_title=JAMA Oncol.; citation_title=Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial; citation_author=E Martinelli; citation_volume=7; citation_publication_date=2021; citation_pages=1529-1535; citation_doi=10.1001/jamaoncol.2021.2915; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=The future of liquid biopsy; citation_author=C Alix-Panabi√®res; citation_volume=579; citation_publication_date=2020; citation_pages=S9; citation_doi=10.1038/d41586-020-00844-5; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Eur. J. Cancer; citation_title=New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1); citation_author=EA Eisenhauer; citation_volume=45; citation_publication_date=2009; citation_pages=228-247; citation_doi=10.1016/j.ejca.2008.10.026; citation_id=CR25">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance; citation_author=M Ali; citation_volume=8; citation_publication_date=2017; citation_doi=10.1038/ncomms15617; citation_id=CR26">
    <meta name="citation_reference" content="citation_journal_title=Eur. J. Cancer; citation_title=Treatment sequencing in metastatic colorectal cancer; citation_author=DP Modest, S Pant, A Sartore-Bianchi; citation_volume=109; citation_publication_date=2019; citation_pages=70-83; citation_doi=10.1016/j.ejca.2018.12.019; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=The genomic landscape of response to EGFR blockade in colorectal cancer; citation_author=A Bertotti; citation_volume=526; citation_publication_date=2015; citation_pages=263-267; citation_doi=10.1038/nature14969; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=Oncologist; citation_title=HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer; citation_author=A Sartore-Bianchi; citation_volume=24; citation_publication_date=2019; citation_pages=1395-1402; citation_doi=10.1634/theoncologist.2018-0785; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=ESMO Open; citation_title=Maximising clinical benefit with adequate patient management beyond the second line in mCRC; citation_author=G Argiles, D Arnold, G Prager, AF Sobrero, E Cutsem; citation_volume=4; citation_publication_date=2019; citation_pages=e000495; citation_doi=10.1136/esmoopen-2019-000495; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=Clin. Colorectal Cancer; citation_title=Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis; citation_author=D Rossini; citation_volume=19; citation_publication_date=2020; citation_pages=191-199; citation_doi=10.1016/j.clcc.2020.03.009; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial; citation_author=KH Khan; citation_volume=8; citation_publication_date=2018; citation_pages=1270-1285; citation_doi=10.1158/2159-8290.CD-17-0891; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer; citation_author=AR Thierry; citation_volume=23; citation_publication_date=2017; citation_pages=4578-4591; citation_doi=10.1158/1078-0432.CCR-17-0232; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=Cancer Res.; citation_title=PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies; citation_author=A Sartore-Bianchi; citation_volume=69; citation_publication_date=2009; citation_pages=1851-1857; citation_doi=10.1158/0008-5472.CAN-08-2466; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case‚Äìcontrol study; citation_author=C Cremolini; citation_volume=28; citation_publication_date=2017; citation_pages=3009-3014; citation_doi=10.1093/annonc/mdx546; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer; citation_author=A Bardelli; citation_volume=3; citation_publication_date=2013; citation_pages=658-673; citation_doi=10.1158/2159-8290.CD-12-0558; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers; citation_author=AR Parikh; citation_volume=25; citation_publication_date=2019; citation_pages=1415-1421; citation_doi=10.1038/s41591-019-0561-9; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer; citation_author=M Russo; citation_volume=6; citation_publication_date=2016; citation_pages=147-153; citation_doi=10.1158/2159-8290.CD-15-1283; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC); citation_author=S Siena; citation_volume=32; citation_publication_date=2021; citation_pages=S530‚ÄìS582; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=Gut; citation_title=High hospital research participation and improved colorectal cancer survival outcomes: a population-based study; citation_author=A Downing; citation_volume=66; citation_publication_date=2017; citation_pages=89-96; citation_doi=10.1136/gutjnl-2015-311308; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Clin. Oncol.; citation_title=Liquid biopsy enters the clinic‚Äîimplementation issues and future challenges; citation_author=M Ignatiadis, GW Sledge, SS Jeffrey; citation_volume=18; citation_publication_date=2021; citation_pages=297-312; citation_doi=10.1038/s41571-020-00457-x; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=Clin. Colorectal Cancer; citation_title=Rationale and study design of the PARERE trial: randomized phase ii study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients; citation_author=R Moretto; citation_volume=20; citation_publication_date=2021; citation_pages=314-317; citation_doi=10.1016/j.clcc.2021.07.001; citation_id=CR42">
    <meta name="citation_reference" content="Strickler, J. H. et al. PULSE: a randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). J. Clin. Oncol. 
                  https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143
                  
                 (2021).">
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects; citation_author=; citation_volume=310; citation_publication_date=2013; citation_pages=2191-2194; citation_doi=10.1001/jama.2013.281053; citation_id=CR44">
    <meta name="citation_reference" content="citation_journal_title=Anal. Chem.; citation_title=High-throughput droplet digital PCR system for absolute quantitation of DNA copy number; citation_author=BJ Hindson; citation_volume=83; citation_publication_date=2011; citation_pages=8604-8610; citation_doi=10.1021/ac202028g; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=Nat. Protoc.; citation_title=Detecting ultralow-frequency mutations by Duplex Sequencing; citation_author=SR Kennedy; citation_volume=9; citation_publication_date=2014; citation_pages=2586-2606; citation_doi=10.1038/nprot.2014.170; citation_id=CR46">
    <meta name="citation_reference" content="citation_journal_title=Proc. Natl Acad. Sci. USA; citation_title=Detection of ultra-rare mutations by next-generation sequencing; citation_author=MW Schmitt; citation_volume=109; citation_publication_date=2012; citation_pages=14508-14513; citation_doi=10.1073/pnas.1208715109; citation_id=CR47">
    <meta name="citation_reference" content="citation_journal_title=Clin. Colorectal Cancer; citation_title=A genomic analysis workflow for colorectal cancer precision oncology; citation_author=G Corti; citation_volume=18; citation_publication_date=2019; citation_pages=91-101; citation_doi=10.1016/j.clcc.2019.02.008; citation_id=CR48">
    <meta name="citation_reference" content="citation_journal_title=ESMO Open; citation_title=Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients; citation_author=G Crisafulli; citation_volume=4; citation_publication_date=2019; citation_pages=e000572; citation_doi=10.1136/esmoopen-2019-000572; citation_id=CR49">
    <meta name="citation_author" content="Sartore-Bianchi, Andrea">
    <meta name="citation_author_institution" content="Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy">
    <meta name="citation_author_institution" content="Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy">
    <meta name="citation_author" content="Pietrantonio, Filippo">
    <meta name="citation_author_institution" content="Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy">
    <meta name="citation_author" content="Lonardi, Sara">
    <meta name="citation_author_institution" content="Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy">
    <meta name="citation_author" content="Mussolin, Benedetta">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author" content="Rua, Francesco">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author" content="Crisafulli, Giovanni">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author_institution" content="Department of Oncology, University of Turin, Turin, Italy">
    <meta name="citation_author" content="Bartolini, Alice">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author" content="Fenocchio, Elisabetta">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author" content="Amatu, Alessio">
    <meta name="citation_author_institution" content="Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy">
    <meta name="citation_author" content="Manca, Paolo">
    <meta name="citation_author_institution" content="Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy">
    <meta name="citation_author" content="Bergamo, Francesca">
    <meta name="citation_author_institution" content="Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy">
    <meta name="citation_author" content="Tosi, Federica">
    <meta name="citation_author_institution" content="Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy">
    <meta name="citation_author" content="Mauri, Gianluca">
    <meta name="citation_author_institution" content="Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy">
    <meta name="citation_author_institution" content="IFOM, FIRC Institute of Molecular Oncology, Milan, Italy">
    <meta name="citation_author" content="Ambrosini, Margherita">
    <meta name="citation_author_institution" content="Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy">
    <meta name="citation_author" content="Daniel, Francesca">
    <meta name="citation_author_institution" content="Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy">
    <meta name="citation_author" content="Torri, Valter">
    <meta name="citation_author_institution" content="Mario Negri Institute for Pharmacological Research-IRCCS, Milan, Italy">
    <meta name="citation_author" content="Vanzulli, Angelo">
    <meta name="citation_author_institution" content="Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy">
    <meta name="citation_author_institution" content="Department of Services, Grande Ospedale Metropolitano Niguarda, Milan, Italy">
    <meta name="citation_author" content="Regge, Daniele">
    <meta name="citation_author_institution" content="Department of Surgical Sciences, University of Turin, Turin, Italy">
    <meta name="citation_author_institution" content="Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author" content="Cappello, Giovanni">
    <meta name="citation_author_institution" content="Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author" content="Marchi√≤, Caterina">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author_institution" content="Department of Medical Sciences, University of Turin, Turin, Italy">
    <meta name="citation_author" content="Berrino, Enrico">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author_institution" content="Department of Medical Sciences, University of Turin, Turin, Italy">
    <meta name="citation_author" content="Sapino, Anna">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author_institution" content="Department of Medical Sciences, University of Turin, Turin, Italy">
    <meta name="citation_author" content="Marsoni, Silvia">
    <meta name="citation_author_institution" content="IFOM, FIRC Institute of Molecular Oncology, Milan, Italy">
    <meta name="citation_author" content="Siena, Salvatore">
    <meta name="citation_author_institution" content="Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy">
    <meta name="citation_author_institution" content="Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy">
    <meta name="citation_author" content="Bardelli, Alberto">
    <meta name="citation_author_institution" content="Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy">
    <meta name="citation_author_institution" content="Department of Oncology, University of Turin, Turin, Italy">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial">
    <meta name="twitter:description" content="Nature Medicine - In a phase 2 trial, monitoring tumor resistance mutations in blood using liquid biopsies allowed rationally guided subsequent therapy with anti-EGFR antibodies in patients with...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-022-01886-0">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial - Nature Medicine">
    <meta property="og:description" content="In a phase 2 trial, monitoring tumor resistance mutations in blood using liquid biopsies allowed rationally guided subsequent therapy with anti-EGFR antibodies in patients with colorectal cancer.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyMCIgaGVpZ2h0PSIyMCI+PHBhdGggZD0iTTcgMGExIDEgMCAxIDEgMCAySDIuNmMtLjM3MSAwLS42LjIwOS0uNi41djE1YzAgLjI5MS4yMjkuNS42LjVoMTQuOGMuMzcxIDAgLjYtLjIwOS42LS41VjEzYTEgMSAwIDAgMSAyIDB2NC41YzAgMS40MzgtMS4xNjIgMi41LTIuNiAyLjVIMi42QzEuMTYyIDIwIDAgMTguOTM4IDAgMTcuNXYtMTVDMCAxLjA2MiAxLjE2MiAwIDIuNiAwem02IDBoNmwuMDc1LjAwMy4xMjYuMDE3LjExMS4wMy4xMTEuMDQ0LjA5OC4wNTIuMDk2LjA2Ny4wOS4wOGExIDEgMCAwIDEgLjA5Ny4xMTJsLjA3MS4xMS4wNTQuMTE0LjAzNS4xMDUuMDMuMTQ4TDIwIDF2NmExIDEgMCAwIDEtMiAwVjMuNDE0bC02LjY5MyA2LjY5M2ExIDEgMCAwIDEtMS40MTQtMS40MTRMMTYuNTg0IDJIMTNhMSAxIDAgMCAxLS45OTMtLjg4M0wxMiAxYTEgMSAwIDAgMSAxLTEiLz48L3N2Zz4=");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-022-01886-0;doi=10.1038/s41591-022-01886-0;subjmeta=1504,1885,308,575,631,67,692;kwrd=Colorectal+cancer,Translational+research">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=1101942288&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01886-0%26doi%3D10.1038/s41591-022-01886-0%26subjmeta%3D1504,1885,308,575,631,67,692%26kwrd%3DColorectal+cancer,Translational+research">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=1101942288&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01886-0%26doi%3D10.1038/s41591-022-01886-0%26subjmeta%3D1504,1885,308,575,631,67,692%26kwrd%3DColorectal+cancer,Translational+research"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-022-01886-0"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01886-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01886-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2022-08-01">01 August 2022</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial</h1>
                    <ul class="c-article-author-list c-article-author-list--short js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Andrea-Sartore_Bianchi-Aff1-Aff2" data-author-popup="auth-Andrea-Sartore_Bianchi-Aff1-Aff2" data-author-search="Sartore-Bianchi, Andrea" data-track-context="researcher popup with no profile" data-track-index="1_25">Andrea Sartore-Bianchi</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0780-0409"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0780-0409</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Filippo-Pietrantonio-Aff3" data-author-popup="auth-Filippo-Pietrantonio-Aff3" data-author-search="Pietrantonio, Filippo" data-track-context="researcher popup with no profile" data-track-index="2_25">Filippo Pietrantonio</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-8530-8420"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-8530-8420</a></span><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sara-Lonardi-Aff4" data-author-popup="auth-Sara-Lonardi-Aff4" data-author-search="Lonardi, Sara" data-track-context="researcher popup with no profile" data-track-index="3_25">Sara Lonardi</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-7593-8138"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-7593-8138</a></span><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Benedetta-Mussolin-Aff5" data-author-popup="auth-Benedetta-Mussolin-Aff5" data-author-search="Mussolin, Benedetta" data-track-context="researcher popup with no profile" data-track-index="4_25">Benedetta Mussolin</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Francesco-Rua-Aff5" data-author-popup="auth-Francesco-Rua-Aff5" data-author-search="Rua, Francesco" data-track-context="researcher popup with no profile" data-track-index="5_25">Francesco Rua</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Giovanni-Crisafulli-Aff5-Aff6" data-author-popup="auth-Giovanni-Crisafulli-Aff5-Aff6" data-author-search="Crisafulli, Giovanni" data-track-context="researcher popup with no profile" data-track-index="6_25">Giovanni Crisafulli</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-5511-1555"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-5511-1555</a></span><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a>,<a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Alice-Bartolini-Aff5" data-author-popup="auth-Alice-Bartolini-Aff5" data-author-search="Bartolini, Alice" data-track-context="researcher popup with no profile" data-track-index="7_25">Alice Bartolini</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Elisabetta-Fenocchio-Aff5" data-author-popup="auth-Elisabetta-Fenocchio-Aff5" data-author-search="Fenocchio, Elisabetta" data-track-context="researcher popup with no profile" data-track-index="8_25">Elisabetta Fenocchio</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6679-0955"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6679-0955</a></span><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Alessio-Amatu-Aff2" data-author-popup="auth-Alessio-Amatu-Aff2" data-author-search="Amatu, Alessio" data-track-context="researcher popup with no profile" data-track-index="9_25">Alessio Amatu</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-5396-3378"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-5396-3378</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Paolo-Manca-Aff3" data-author-popup="auth-Paolo-Manca-Aff3" data-author-search="Manca, Paolo" data-track-context="researcher popup with no profile" data-track-index="10_25">Paolo Manca</a><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Francesca-Bergamo-Aff4" data-author-popup="auth-Francesca-Bergamo-Aff4" data-author-search="Bergamo, Francesca" data-track-context="researcher popup with no profile" data-track-index="11_25">Francesca Bergamo</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Federica-Tosi-Aff2" data-author-popup="auth-Federica-Tosi-Aff2" data-author-search="Tosi, Federica" data-track-context="researcher popup with no profile" data-track-index="12_25">Federica Tosi</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Gianluca-Mauri-Aff1-Aff7" data-author-popup="auth-Gianluca-Mauri-Aff1-Aff7" data-author-search="Mauri, Gianluca" data-track-context="researcher popup with no profile" data-track-index="13_25">Gianluca Mauri</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-7646-0973"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-7646-0973</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Margherita-Ambrosini-Aff3" data-author-popup="auth-Margherita-Ambrosini-Aff3" data-author-search="Ambrosini, Margherita" data-track-context="researcher popup with no profile" data-track-index="14_25">Margherita Ambrosini</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-4131-2409"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-4131-2409</a></span><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Francesca-Daniel-Aff4" data-author-popup="auth-Francesca-Daniel-Aff4" data-author-search="Daniel, Francesca" data-track-context="researcher popup with no profile" data-track-index="15_25">Francesca Daniel</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Valter-Torri-Aff8" data-author-popup="auth-Valter-Torri-Aff8" data-author-search="Torri, Valter" data-track-context="researcher popup with no profile" data-track-index="16_25">Valter Torri</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Angelo-Vanzulli-Aff1-Aff9" data-author-popup="auth-Angelo-Vanzulli-Aff1-Aff9" data-author-search="Vanzulli, Angelo" data-track-context="researcher popup with no profile" data-track-index="17_25">Angelo Vanzulli</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Daniele-Regge-Aff10-Aff11" data-author-popup="auth-Daniele-Regge-Aff10-Aff11" data-author-search="Regge, Daniele" data-track-context="researcher popup with no profile" data-track-index="18_25">Daniele Regge</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a>,<a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Giovanni-Cappello-Aff11" data-author-popup="auth-Giovanni-Cappello-Aff11" data-author-search="Cappello, Giovanni" data-track-context="researcher popup with no profile" data-track-index="19_25">Giovanni Cappello</a><sup class="u-js-hide"><a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Caterina-Marchi_-Aff5-Aff12" data-author-popup="auth-Caterina-Marchi_-Aff5-Aff12" data-author-search="Marchi√≤, Caterina" data-track-context="researcher popup with no profile" data-track-index="20_25">Caterina Marchi√≤</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a>,<a href="#Aff12" tabindex="-1">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Enrico-Berrino-Aff5-Aff12" data-author-popup="auth-Enrico-Berrino-Aff5-Aff12" data-author-search="Berrino, Enrico" data-track-context="researcher popup with no profile" data-track-index="21_25">Enrico Berrino</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6728-5619"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6728-5619</a></span><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a>,<a href="#Aff12" tabindex="-1">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Anna-Sapino-Aff5-Aff12" data-author-popup="auth-Anna-Sapino-Aff5-Aff12" data-author-search="Sapino, Anna" data-track-context="researcher popup with no profile" data-track-index="22_25">Anna Sapino</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-3542-9571"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3542-9571</a></span><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a>,<a href="#Aff12" tabindex="-1">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Silvia-Marsoni-Aff7" data-author-popup="auth-Silvia-Marsoni-Aff7" data-author-search="Marsoni, Silvia" data-track-context="researcher popup with no profile" data-track-index="23_25">Silvia Marsoni</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Salvatore-Siena-Aff1-Aff2" data-author-popup="auth-Salvatore-Siena-Aff1-Aff2" data-author-search="Siena, Salvatore" data-track-context="researcher popup with no profile" data-track-index="24_25">Salvatore Siena</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2681-2846"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2681-2846</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 25 authors for this article" title="Show all 25 authors for this article">‚Ä¶</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Alberto-Bardelli-Aff5-Aff6" data-author-popup="auth-Alberto-Bardelli-Aff5-Aff6" data-author-search="Bardelli, Alberto" data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="25_25">Alberto Bardelli<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-1647-5070"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-1647-5070</a></span><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a>,<a href="#Aff6" tabindex="-1">6</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;28</b>,&nbsp;<span class="u-visually-hidden">pages </span>1612‚Äì1618 (<span data-test="article-publication-year">2022</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">24k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">154 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">85 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-022-01886-0/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that <i>RAS</i>, <i>BRAF</i> and <i>EGFR</i> mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of <i>RAS</i>/<i>BRAF</i>/<i>EGFR</i> mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: <a href="https://clinicaltrials.gov/ct2/show/NCT03227926">NCT03227926</a>; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue-<i>RAS</i> WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41598-021-03197-9/MediaObjects/41598_2021_3197_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41598-021-03197-9?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41598-021-03197-9">Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with <i>RAS</i> wild-type metastatic colorectal cancer
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">10 December 2021</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-024-51536-x/MediaObjects/41467_2024_51536_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41467-024-51536-x?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41467-024-51536-x">Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">23 August 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41416-023-02366-z/MediaObjects/41416_2023_2366_Figa_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41416-023-02366-z?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41416-023-02366-z">The emergence of <i>RAS</i> mutations in patients with <i>RAS</i> wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">24 July 2023</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749520671,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>The 5-year relative overall survival (OS) of patients with stage IV mCRC is lower than 15%<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209‚Äì249 (2021)." href="/articles/s41591-022-01886-0#ref-CR1" id="ref-link-section-d73924273e871">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Siegel, R. L., Miller, K. D., Fuchs, H. E. &amp; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7‚Äì33 (2021)." href="/articles/s41591-022-01886-0#ref-CR2" id="ref-link-section-d73924273e874">2</a></sup>. Over a decade ago, the use of targeted agents, such as the anti-EGFR antibodies cetuximab and panitumumab, was shown to improve survival of patients with <i>RAS</i> WT mCRC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Di Nicolantonio, F. et al. Precision oncology in metastatic colorectal cancer‚Äîfrom biology to medicine. Nat. Rev. Clin. Oncol. 18, 506‚Äì525 (2021)." href="/articles/s41591-022-01886-0#ref-CR3" id="ref-link-section-d73924273e881">3</a></sup>. However, patients with initial benefit from EGFR blockade almost invariably develop resistance<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Siravegna, G. &amp; Bardelli, A. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. Mol. Oncol. 10, 475‚Äì480 (2016)." href="/articles/s41591-022-01886-0#ref-CR4" id="ref-link-section-d73924273e885">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532‚Äì536 (2012)." href="/articles/s41591-022-01886-0#ref-CR5" id="ref-link-section-d73924273e888">5</a></sup>. From a molecular perspective, acquired resistance to anti-EGFR treatment is mostly associated with two main mechanisms: the first involves the emergence of activating mutations in <i>EGFR</i> downstream effectors (primarily, <i>NRAS</i> and <i>BRAF</i>), whereas the second relies on mutations in the <i>EGFR</i> extracellular domain (ECD) that impair antibody binding to its target<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532‚Äì536 (2012)." href="#ref-CR5" id="ref-link-section-d73924273e905">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin. Cancer Res 21, 2157‚Äì2166 (2015)." href="#ref-CR6" id="ref-link-section-d73924273e905_1">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705‚Äì5712 (2008)." href="#ref-CR7" id="ref-link-section-d73924273e905_2">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Montagut, C. et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA Analyses: a phase 2 randomized clinical trial. JAMA Oncol. 4, e175245 (2018)." href="/articles/s41591-022-01886-0#ref-CR8" id="ref-link-section-d73924273e908">8</a></sup>.</p><p>In 2015, we and others reported that mutant <i>KRAS</i> clones, which emerge in blood during EGFR blockade, decline upon withdrawal of anti-EGFR antibodies, indicating that clonal evolution continues beyond clinical progression<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795‚Äì801 (2015)." href="#ref-CR9" id="ref-link-section-d73924273e918">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. 26, 731‚Äì736 (2015)." href="#ref-CR10" id="ref-link-section-d73924273e918_1">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243‚Äì249 (2019)." href="#ref-CR11" id="ref-link-section-d73924273e918_2">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann. Oncol. 29, 119‚Äì126 (2018)." href="/articles/s41591-022-01886-0#ref-CR12" id="ref-link-section-d73924273e921">12</a></sup>. Interestingly, <i>RAS</i> and <i>EGFR</i> ECD clones have been reported to decay in ctDNA with a half-life of 3.7‚Äâmonths and 4.7‚Äâmonths, respectively<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243‚Äì249 (2019)." href="/articles/s41591-022-01886-0#ref-CR11" id="ref-link-section-d73924273e931">11</a></sup>. The decay of <i>KRAS</i> mutations in blood upon anti-EGFR antibody withdrawal is an indication of clonal evolution during therapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Siravegna, G., Marsoni, S., Siena, S. &amp; Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531‚Äì548 (2017)." href="/articles/s41591-022-01886-0#ref-CR13" id="ref-link-section-d73924273e939">13</a></sup>.</p><p>Treatment of patients who initially respond and then progress after therapeutic EGFR blockade with cetuximab or panitumumab remains an unmet clinical need for at least three reasons. First, the molecular bases of relapse are patient specific and difficult to define, as tissue biopsies at the time of progression cannot be systematically performed in clinical practice and have intrinsic risks<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Siravegna, G., Marsoni, S., Siena, S. &amp; Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531‚Äì548 (2017)." href="/articles/s41591-022-01886-0#ref-CR13" id="ref-link-section-d73924273e946">13</a></sup>. Second, <i>KRAS</i>, <i>NRAS</i> and <i>EGFR</i> ECD acquired mutations, which occur in about 40% of the cases, are often highly heterogeneous, and the corresponding mutant proteins are difficult to target pharmacologically<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Di Nicolantonio, F. et al. Precision oncology in metastatic colorectal cancer‚Äîfrom biology to medicine. Nat. Rev. Clin. Oncol. 18, 506‚Äì525 (2021)." href="/articles/s41591-022-01886-0#ref-CR3" id="ref-link-section-d73924273e959">3</a></sup>. Third, late-line standard therapeutic options beyond second-line treatment in patients with mCRC are poorly effective and ridden with meaningful toxicities<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909‚Äì1919 (2015)." href="/articles/s41591-022-01886-0#ref-CR14" id="ref-link-section-d73924273e964">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303‚Äì312 (2013)." href="/articles/s41591-022-01886-0#ref-CR15" id="ref-link-section-d73924273e967">15</a></sup>. As a result, upon failure of upfront anti-EGFR blockade, patients with <i>RAS</i> and <i>BRAF</i> WT mCRC and no targetable alterations, such as <i>ERBB2</i> amplification<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Siena, S., Marsoni, S. &amp; Sartore-Bianchi, A. Breaking barriers in HER2+ cancers. Cancer Cell 38, 317‚Äì319 (2020)." href="/articles/s41591-022-01886-0#ref-CR16" id="ref-link-section-d73924273e980">16</a></sup> or <i>NTRK</i> fusions<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Amatu, A. et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann. Oncol. 30, viii5‚Äìviii15 (2019)." href="/articles/s41591-022-01886-0#ref-CR17" id="ref-link-section-d73924273e988">17</a></sup>, usually undergo additional lines of standard cytotoxic regimens and/or anti-angiogenic drugs<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Cancer Netw. 19, 329‚Äì359 (2021)." href="/articles/s41591-022-01886-0#ref-CR18" id="ref-link-section-d73924273e992">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Yoshino, T. et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann. Oncol. 29, 44‚Äì70 (2018)." href="/articles/s41591-022-01886-0#ref-CR19" id="ref-link-section-d73924273e995">19</a></sup>. None of the latter options is currently based on a diagnostic molecular testing<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Cancer Netw. 19, 329‚Äì359 (2021)." href="/articles/s41591-022-01886-0#ref-CR18" id="ref-link-section-d73924273e999">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Yoshino, T. et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann. Oncol. 29, 44‚Äì70 (2018)." href="/articles/s41591-022-01886-0#ref-CR19" id="ref-link-section-d73924273e1002">19</a></sup>. In this setting, retreatment with anti-EGFR monoclonal antibodies may be used as late-line therapy in clinical practice<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Mauri, G. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat. Rev. 73, 41‚Äì53 (2019)." href="/articles/s41591-022-01886-0#ref-CR20" id="ref-link-section-d73924273e1006">20</a></sup>. In this context, rechallenge is defined as retreatment with a therapeutic agent to which the tumor has responded and then progressed upon<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Mauri, G. et al. Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities. Cancer Treat. Rev. 91, 102112 (2020)." href="/articles/s41591-022-01886-0#ref-CR21" id="ref-link-section-d73924273e1010">21</a></sup>. Empirical anti-EGFR rechallenge therapy has a 8‚Äì20% response rate and manageable toxicities<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Mauri, G. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat. Rev. 73, 41‚Äì53 (2019)." href="/articles/s41591-022-01886-0#ref-CR20" id="ref-link-section-d73924273e1014">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Cremolini, C. et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.JAMA Oncol. 5, 343‚Äì350 (2019)." href="/articles/s41591-022-01886-0#ref-CR22" id="ref-link-section-d73924273e1017">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 7, 1529‚Äì1535 (2021)." href="/articles/s41591-022-01886-0#ref-CR23" id="ref-link-section-d73924273e1020">23</a></sup>. Despite much promising retrospective data, liquid biopsies have never been used interventionally to time and tailor anti-EGFR rechallenge in patients with mCRC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Mauri, G. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat. Rev. 73, 41‚Äì53 (2019)." href="/articles/s41591-022-01886-0#ref-CR20" id="ref-link-section-d73924273e1025">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Cremolini, C. et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.JAMA Oncol. 5, 343‚Äì350 (2019)." href="#ref-CR22" id="ref-link-section-d73924273e1028">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 7, 1529‚Äì1535 (2021)." href="#ref-CR23" id="ref-link-section-d73924273e1028_1">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Alix-Panabi√®res, C. The future of liquid biopsy. Nature 579, S9 (2020)." href="/articles/s41591-022-01886-0#ref-CR24" id="ref-link-section-d73924273e1031">24</a></sup>. To fill this gap, we conceived CHRONOS, a multicenter, open-label, single-arm phase 2 trial of panitumumab anti-EGFR therapy rechallenge guided by prospective and interventional assessment of <i>RAS</i>, <i>BRAF</i> and <i>EGFR</i> ECD mutational status in ctDNA. To our knowledge, this is the first time that liquid biopsies have been prospectively used to define treatment choice with an anti-EGFR antibody in patients with mCRC.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Treatment characteristics of patients enrolled in CHRONOS</h3><p>CHRONOS was designed to test the hypothesis that assessing the presence/absence of resistance mutations in blood of patients with mCRC could be used to guide additional lines of anti-EGFR blockade (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig1">1</a>). To this end, we decided to enroll in CHRONOS only those patients in whom the ctDNA levels of all the mutations that we monitored were below detection, which we refer to as the ‚Äòzero mutation ctDNA triage‚Äô (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig5">1</a>). This approach was set pragmatically to ensure timely and effective therapeutic intervention, considering the need to rapidly initiate the next round of treatment. A total of 52 patients were screened, and 27 with no detectable alterations in <i>RAS</i>, <i>BRAF</i> and <i>EGFR</i> ECD in ctDNA were enrolled for anti-EGFR treatment (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig1">1</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig6">2</a>). Patient characteristics are representative of a third or further line population of patients with mCRC (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-01886-0#Tab1">1</a>). The median number of previous anti-cancer treatments was three, and the previous anti-EGFR treatment most commonly administered was panitumumab (15/27, 55%), predominantly in the first line (21/27, 78%) and always in combination with a cytotoxic backbone. All patients had a microsatellite stable (MSS) tumor. The primary endpoint of the trial was overall response rate (ORR) to panitumumab rechallenge according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228‚Äì247 (2009)." href="/articles/s41591-022-01886-0#ref-CR25" id="ref-link-section-d73924273e1081">25</a></sup>), and the secondary endpoints were progression-free survival (PFS), OS and toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Fig. 1"><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01886-0/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="333"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p>CONSORT diagram and molecular screening of the CHRONOS trial. Results of ctDNA ddPCR analysis and distribution of <i>RAS</i>, <i>BRAF</i> and <i>EGFR</i> ECD mutations in patients screened within the CHRONOS trial. Abbreviations: ctDNA, circulating tumor DNA; ddPCR, droplet digital PCR; ECD, ectodomain.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01886-0/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Main clinicopathological features of patients enrolled in the CHRONOS trial</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-022-01886-0/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec4">Blood detection of <i>RAS/BRAF</i> and <i>EGFR</i> ECD mutations</h3><p>A panel of <i>KRAS</i>, <i>BRAF</i> and <i>EGFR</i> ECD mutations was assessed in ctDNA using a droplet digital PCR (ddPCR)-based assay (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01886-0#Sec9">Methods</a>). A total of 52 patients were screened; of these, 16 (31%) had at least one anti-EGFR resistance-conferring mutation in their ctDNA (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig1">1</a>). Precisely, we found that 13 of 52 (25%) patients had <i>KRAS</i>, four of 52 (8%) had <i>NRAS</i>, one of 52 (2%) had <i>BRAF</i> and three of 52 (6%) had <i>EGFR</i> ECD mutations in their ctDNA. Multiple mutations co-occurred in five of the 16 patients, whereas, in two patients, <i>BRAF</i> and <i>EGFR</i> ECD were the only resistance-conferring mutations, confirming that the addition of these two to the <i>RAS</i> panel optimized patient selection. The variant allele frequency varied between 0.28% and 46.20%. As we and others previously reported<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532‚Äì536 (2012)." href="/articles/s41591-022-01886-0#ref-CR5" id="ref-link-section-d73924273e1682">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann. Oncol. 29, 119‚Äì126 (2018)." href="/articles/s41591-022-01886-0#ref-CR12" id="ref-link-section-d73924273e1685">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Ali, M. et al. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nat. Commun. 8, 15617 (2017)." href="/articles/s41591-022-01886-0#ref-CR26" id="ref-link-section-d73924273e1688">26</a></sup>, codon 61 <i>RAS</i> mutations were among the most frequently identified <i>RAS</i> alleles, with a prevalence of eight of 16 (50%) patients. The high frequency of Q61 variants in ctDNA of patients with mCRC is directly associated with secondary resistance to anti-EGFR antibodies; accordingly, these findings further confirm the emergence of EGFR blockade-specific mutations in CHRONOS<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532‚Äì536 (2012)." href="/articles/s41591-022-01886-0#ref-CR5" id="ref-link-section-d73924273e1698">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann. Oncol. 29, 119‚Äì126 (2018)." href="/articles/s41591-022-01886-0#ref-CR12" id="ref-link-section-d73924273e1701">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Ali, M. et al. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nat. Commun. 8, 15617 (2017)." href="/articles/s41591-022-01886-0#ref-CR26" id="ref-link-section-d73924273e1704">26</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec5">Clinical outcome to panitumumab rechallenge</h3><p>According to the ‚Äòzero mutation ctDNA triage‚Äô, 36 patients were molecularly eligible for panitumumab rechallenge. Of these, 27 received the drug as per trial protocol, six did not meet clinical inclusion criteria, and three were treated otherwise as per physician choice (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig1">1</a>). The median time interval between the screening liquid biopsy and the first dose of panitumumab rechallenge was 21‚Äâdays (range, 9‚Äì44‚Äâdays). The primary endpoint of the trial was met, with eight partial responses (PRs) (six confirmed plus two unconfirmed according to RECIST 1.1) defining an ORR of 30% (95% confidence interval (CI): 12‚Äì47%) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig2">2a</a>). The median duration of response was 17‚Äâweeks (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig2">2b</a>). Stable disease (SD) was achieved in 11 of 27 (40%, 95% CI: 24‚Äì59%) patients and lasted more than 4‚Äâmonths in nine of 11 (82%) patients. A disease control rate (defined as PR plus SD &gt;4‚Äâmonths) was, therefore, obtained in 17 patients (63%, 95% CI: 41‚Äì78%). Taking into account that patients had received, and failed, a median of three prior regimens of systemic treatments, the depth ‚Äî in terms of percentage tumor shrinkage ‚Äî and the dynamic of response achieved by single-agent panitumumab (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig2">2</a>) is remarkable and favorably compares with third-line standard-of-care treatments such as regorafenib or trifluridine‚Äìtipiracil<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909‚Äì1919 (2015)." href="/articles/s41591-022-01886-0#ref-CR14" id="ref-link-section-d73924273e1728">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303‚Äì312 (2013)." href="/articles/s41591-022-01886-0#ref-CR15" id="ref-link-section-d73924273e1731">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Modest, D. P., Pant, S. &amp; Sartore-Bianchi, A. Treatment sequencing in metastatic colorectal cancer. Eur. J. Cancer109, 70‚Äì83 (2019)." href="/articles/s41591-022-01886-0#ref-CR27" id="ref-link-section-d73924273e1734">27</a></sup>. Interestingly, objective responses occurred also in patients with right-sided primary tumors and in those heavily pretreated with more than four previous lines (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig7">3</a>). A 16-week PFS further corroborates the response findings (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig8">4a</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig2">2</a>). The median OS was 55‚Äâweeks (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig8">4b</a>). The anti-EGFR rechallenge was overall well-tolerated with manageable side effects as expected for this class of drugs. The safety analysis included all patients who received at least one dose of panitumumab. There were no permanent treatment interruptions due to adverse events nor treatment withdraws requested by patients. Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">1</a> details all CTCAE grade treatment-related adverse events, including the five patients treated with panitumumab monotherapy according to previous protocol version 2.1. No grade 5 adverse events were reported; grade 3/4 toxicities were observed in seven of 32 (22%) patients. The most common severe adverse events were skin rash (3/32 patients, 9%), folliculitis (2/32, 6%), paronychia (1/32, 3%) and dermatitis (1/32, 3%). Dose reduction and treatment delay was required in three of 32 (9%) patients due to G3 skin rash, folliculitis and skin rash and dermatitis. Of note, 12 of 32 (37%) patients had primary prophylaxis with tetracycline antibiotics as per clinical choice, but the number of cutaneous events did not differ from those who did not receive such treatment.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Fig. 2"><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01886-0/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="233"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p>Waterfall plot depicts best responses to panitumumab rechallenge within the CHRONOS trial according to RECIST 1.1 (<b>a</b>). Spider plot displays best responses according to RECIST 1.1 and duration of response to panitumumab rechallenge (<b>b</b>). Magenta, progressive disease; gray, stable disease; blue, partial response; black, unconfirmed partial response; * progressive disease exclusively due to the onset of a new metastatic lesion.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01886-0/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec6">Detection of resistance mutations in ctDNA</h3><p>It has been suggested that time thresholds based on mathematical modeling of the kinetic of decay of <i>RAS/EGFR</i> mutant clones can be used to define an optimal timing of rechallenge treatment with anti-EGFR antibodies in patients with mCRC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243‚Äì249 (2019)." href="/articles/s41591-022-01886-0#ref-CR11" id="ref-link-section-d73924273e1789">11</a></sup>. In light of these findings, we calculated for each patient the screening time interval (STI), defined as the time intercurred between the dates of the last dose of previous anti-EGFR and that of the CHRONOS screening (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig3">3</a>). The median STI was 11.5‚Äâmonths. A specific time threshold differentiating patients with WT ctDNA from patients with mutated ctDNA was not present. Moreover, there was no correlation between length of STI and probability of response, further suggesting that ‚Äòzero mutation ctDNA‚Äô status is the main predictive factor for anti-EGFR rechallenge efficacy. Overall, these observations suggest that a predefined time limit<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243‚Äì249 (2019)." href="/articles/s41591-022-01886-0#ref-CR11" id="ref-link-section-d73924273e1796">11</a></sup> might be ineffectual for a clinical selection of cases to be rechallenged, whereas ctDNA measurement enables definition of potentially responding patients.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Fig. 3"><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01886-0/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="348"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p>Tree graph describing ctDNA <i>RAS/BRAF/EGFR</i> status of patients screened for CHRONOS enrollment according to the time interval between the end of the last anti-EGFR course and the date of the CHRONOS ctDNA screening. Top: patients with WT sample; color-coded objective response to rechallenge with panitumumab on a time scale displaying PFS. Bottom: patients with mutated sample and mutations retrieved leading to CHRONOS screening failure. Œ±EGFR, anti-EGFR. Abbreviations: MT, mutant; WT, wild-type.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01886-0/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec7">Molecular profiling before and after anti-EGFR rechallenge</h3><p>We studied archival formalin-fixed paraffin-embedded (FFPE) samples, gathered before panitumumab rechallenge, as well as ctDNA collected at baseline and at progressive disease (PD) to panitumumab rechallenge (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig4">4</a>). Tissue samples were analyzed using the next-generation sequencing (NGS) Oncomine Comprehensive Assay version 3 (OCAv3), whereas ctDNA samples were genotyped by a high-sensitivity NGS panel assay based on a custom Duplex Sequencing (DS) workflow (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01886-0#Sec9">Methods</a>). NGS analysis on archival FFPE samples obtained before panitumumab rechallenge revealed an <i>ERBB2</i> amplification in two patients (INT-001 and NIG-012), one of whom (INT-001) also harbored the hotspot <i>ERBB2</i> p.V777L mutation (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig4">4</a>). It was previously reported by us and others that <i>ERBB2</i> mutations confer resistance to EGFR blockade in CRC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Bertotti, A. et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526, 263‚Äì267 (2015)." href="/articles/s41591-022-01886-0#ref-CR28" id="ref-link-section-d73924273e1849">28</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Sartore-Bianchi, A. et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 24, 1395‚Äì1402 (2019)." href="/articles/s41591-022-01886-0#ref-CR29" id="ref-link-section-d73924273e1852">29</a></sup>. Of note, both INT-001 and NIG-012 had PD as best response to panitumumab rechallenge.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Fig. 4"><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01886-0/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="481"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p>Alterations identified by NGS on tissue samples collected before CHRONOS enrollment (upper panel), on ctDNA at baseline to panitumumab rechallenge (middle panel) and on ctDNA at progression to panitumumab rechallenge (lower panel). As per inclusion criteria, all patients enrolled achieved complete or partial response to prior anti-EGFR antibodies either as monotherapy or in combination with cytotoxic agents. Mutations in the genes (<i>NRAS/KRAS/BRAF/EGFR</i>) of the molecular screening panel and <i>KRAS/EGFR</i> amplifications are highlighted in yellow.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01886-0/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Although tissue was available in all but one of the enrolled patients, plasma collected (before panitumumab rechallenge within the CHRONOS trial) was sometimes limited, as it was used primarily for the screening ddPCR assays required to enroll patients in the trial. In most cases (18/27), there was sufficient ctDNA left to also perform high-sensitivity NGS panel analysis on plasma before rechallenge. Interestingly, this analysis revealed, in a subset of the patients, the presence of <i>MAP2K1</i>, <i>PTEN</i>, <i>SMAD4</i> and <i>PIK3CA</i> mutations previously associated with resistance to EGFR blockade and that were not captured by the ddPCR assay (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">2</a>).</p><p>NGS panel analysis was also performed on all the patients (21/27, 78%) for whom plasma collected at PD after rechallenge was available in sufficient amounts. In this instance, NGS analysis revealed in most of the cases (15/21, 71%) at least one genetic alteration previously linked to resistance to EGFR blockade (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig4">4</a>). The most common mechanisms of resistance identified at panitumumab rechallenge were mutations or amplification in the <i>EGFR</i>, <i>KRAS</i> and <i>NRAS</i> genes, which were observed in ten of 21 (48%) patients. As expected, <i>KRAS</i> and <i>NRAS</i> mutations occurred frequently at position 61. <i>PTEN</i> nonsense mutations were found in four patients, and <i>MET</i> amplification was detected in three patients. Interestingly, in ten of 21 (48%) patients, at least two alterations putatively conferring resistance to anti-EGFR treatment were identified (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig4">4</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">2</a>). Of five patients with evaluable ctDNA analysis and achieving PR, three displayed resistance-conferring mutations at PD (INT-005, NIG-006 and IOV-003) and achieved a PFS of, respectively, 28‚Äâweeks, 28‚Äâweeks and 21‚Äâweeks. Similarly, the two remaining ctDNA-evaluable patients showing PR but with no mutations on ctDNA at CHRONOS progression (IOV-009 and NIG-001) achieved a PFS of 20‚Äâweeks and 27‚Äâweeks, respectively (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig4">4</a>). Of note, resistance mutations were also frequently detected in plasma of patients who did not clinically respond to rechallenge therapy. Because the parallel NGS analyses performed on the same individuals before anti-EGFR rechallenge were negative (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig4">4</a>), the emergence of molecular alterations in the tumors of four of six patients (INT-009, IOV-004, NIG-009 and NIG-014) indicates that a biological pressure was applied by the anti-EGFR antibodies also on the tumors that did not benefit by CHRONOS therapy according to RECIST. In other words, cancer evolution upon EGFR blockade must have occurred also in those patients in whom radiological determination did not highlight a clinical response.</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec8-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec8">Discussion</h2><div class="c-article-section__content" id="Sec8-content"><p>Over 30% of patients with mCRC are eligible for a third or further line of treatment throughout their continuum of care<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Modest, D. P., Pant, S. &amp; Sartore-Bianchi, A. Treatment sequencing in metastatic colorectal cancer. Eur. J. Cancer109, 70‚Äì83 (2019)." href="/articles/s41591-022-01886-0#ref-CR27" id="ref-link-section-d73924273e1948">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Argiles, G., Arnold, D., Prager, G., Sobrero, A. F. &amp; Van Cutsem, E. Maximising clinical benefit with adequate patient management beyond the second line in mCRC. ESMO Open 4, e000495 (2019)." href="/articles/s41591-022-01886-0#ref-CR30" id="ref-link-section-d73924273e1951">30</a></sup>. In this context, retreatment with drugs to which patients had been previously exposed is often adopted in clinical practice despite the lack of biomarkers and of conclusive clinical evidence<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Mauri, G. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat. Rev. 73, 41‚Äì53 (2019)." href="/articles/s41591-022-01886-0#ref-CR20" id="ref-link-section-d73924273e1955">20</a></sup>. In keeping with such empirical practice, rechallenge with anti-EGFR agents is deployed according to the described decay of resistance mechanisms<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243‚Äì249 (2019)." href="/articles/s41591-022-01886-0#ref-CR11" id="ref-link-section-d73924273e1959">11</a></sup>, its manageable toxicity profile and potential induction of tumor shrinkage<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Mauri, G. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat. Rev. 73, 41‚Äì53 (2019)." href="/articles/s41591-022-01886-0#ref-CR20" id="ref-link-section-d73924273e1963">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Cremolini, C. et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.JAMA Oncol. 5, 343‚Äì350 (2019)." href="/articles/s41591-022-01886-0#ref-CR22" id="ref-link-section-d73924273e1966">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 7, 1529‚Äì1535 (2021)." href="/articles/s41591-022-01886-0#ref-CR23" id="ref-link-section-d73924273e1969">23</a></sup>. This strategy is commonly used in clinical practice and is increasingly guided by extended and real-time molecular profiling, despite the lack of prospective data<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Cancer Netw. 19, 329‚Äì359 (2021)." href="/articles/s41591-022-01886-0#ref-CR18" id="ref-link-section-d73924273e1973">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Mauri, G. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat. Rev. 73, 41‚Äì53 (2019)." href="/articles/s41591-022-01886-0#ref-CR20" id="ref-link-section-d73924273e1976">20</a></sup>. We and others previously proposed that ctDNA analysis of anti-EGFR resistance-conferring mutations could be used to direct the selection of patients in this context<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795‚Äì801 (2015)." href="/articles/s41591-022-01886-0#ref-CR9" id="ref-link-section-d73924273e1981">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Siravegna, G., Marsoni, S., Siena, S. &amp; Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531‚Äì548 (2017)." href="/articles/s41591-022-01886-0#ref-CR13" id="ref-link-section-d73924273e1984">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Cremolini, C. et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.JAMA Oncol. 5, 343‚Äì350 (2019)." href="/articles/s41591-022-01886-0#ref-CR22" id="ref-link-section-d73924273e1987">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 7, 1529‚Äì1535 (2021)." href="/articles/s41591-022-01886-0#ref-CR23" id="ref-link-section-d73924273e1990">23</a></sup>.</p><p>CHRONOS is a phase 2 trial assessing the activity and safety of an anti-EGFR rechallenge strategy based on an interventional assessment of <i>RAS</i>, <i>BRAF</i> and <i>EGFR</i> ECD status in ctDNA. Considering the lack of association of clinical factors with the outcomes of anti-EGFR retreatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Rossini, D. et al. Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis. Clin. Colorectal Cancer 19, 191‚Äì199 (2020)." href="/articles/s41591-022-01886-0#ref-CR31" id="ref-link-section-d73924273e2006">31</a></sup>, the use of liquid biopsy to guide patient selection has three main advantages. First, it avoids a potentially ineffective and toxic treatment in the approximately 30% of the patients who are known to carry resistance-conferring mutations owing to previous exposure to EGFR blockade. Second, it empowers treatment decision-making by selecting patients according to real-time monitoring of resistance in tumors using blood as a proxy, independently of pre-defined clinical criteria, such as number of previous therapies, sidedness of primary tumor or a specific timeframe constraint before rechallenge<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243‚Äì249 (2019)." href="/articles/s41591-022-01886-0#ref-CR11" id="ref-link-section-d73924273e2010">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Rossini, D. et al. Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis. Clin. Colorectal Cancer 19, 191‚Äì199 (2020)." href="/articles/s41591-022-01886-0#ref-CR31" id="ref-link-section-d73924273e2013">31</a></sup>. The latter strategy is based on the observation that the average half-life of <i>RAS/EGFR</i> mutant clones, estimated by mathematical modelling of retrospective data, is approximately 4.3‚Äâmonths, hence the recommendation to wait at least 8‚Äâmonths ‚Äî the equivalent of two mutant clone half-lives ‚Äî before rechallenging the patient<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243‚Äì249 (2019)." href="/articles/s41591-022-01886-0#ref-CR11" id="ref-link-section-d73924273e2021">11</a></sup>. Of relevance, we found, instead, that mutant circulating alleles were absent as early as 4‚Äâmonths in patients who achieved PR to rechallenge (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig3">3</a>), whereas resistance-conferring mutations were found in the ctDNA beyond 12‚Äâmonths of anti-EGFR-free interval, underlying the need of personalizing the rechallenge interval to the single tumor, which can be done only via liquid biopsy. Third, it appears to enrich for response. The 30% response rate observed with the CHRONOS chemotherapy-free regimen favorably compares with the response rates of 8% and 21% of two other clinically based studies using rechallenge combination with chemotherapy or immunotherapy in the same setting<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Cremolini, C. et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.JAMA Oncol. 5, 343‚Äì350 (2019)." href="/articles/s41591-022-01886-0#ref-CR22" id="ref-link-section-d73924273e2028">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 7, 1529‚Äì1535 (2021)." href="/articles/s41591-022-01886-0#ref-CR23" id="ref-link-section-d73924273e2031">23</a></sup>. In short, the results of CHRONOS indicate that selecting patients based on ctDNA improves the therapeutic index of anti-EGFR rechallenge by excluding resistant cases otherwise neglected by clinical criteria and by adopting a less toxic, chemotherapy-free panitumumab monotherapy.</p><p>CHRONOS was initially conceived to longitudinally monitor the drop of resistant mutations in blood, as originally reported by us<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795‚Äì801 (2015)." href="/articles/s41591-022-01886-0#ref-CR9" id="ref-link-section-d73924273e2038">9</a></sup> and subsequently confirmed by others<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Khan, K. H. et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 8, 1270‚Äì1285 (2018)." href="/articles/s41591-022-01886-0#ref-CR32" id="ref-link-section-d73924273e2042">32</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Thierry, A. R. et al. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clin. Cancer Res. 23, 4578‚Äì4591 (2017)." href="/articles/s41591-022-01886-0#ref-CR33" id="ref-link-section-d73924273e2045">33</a></sup>. However, in clinical practice, implementation of multiple blood tests to confirm decay of resistant mutations to prompt a rechallenge therapy would be overcostly and impractical. When the approach was indeed attempted in our clinics, the availability of sequential samples, often widely spaced in time between each other, and the time needed to wait for two longitudinal ctDNA measurements (to assess mutation decay) clashed with the need to rapidly initiate the next round of treatment, as clinically required in patients with advanced-line mCRC.</p><p>To bypass these issues, we decided to enroll in CHRONOS only those patients in whom the ctDNA resistance mutations were undetectable. We refer to this strategy as the ‚Äòzero mutation ctDNA triage‚Äô. This pragmatic approach is easily implemented in outpatient clinics and ensures effective turnaround time for timely therapeutic intervention.</p><p>The CHRONOS strategy has limitations and can be further improved. First, the three-gene ddPCR panel molecular screening implemented in CHRONOS could be further refined. In this regard, future studies should consider screening of a larger panel of resistant variants in ctDNA to increase the therapeutic index of anti-EGFR monoclonal antibodies. For example, assessment of <i>MAPK</i> alterations or <i>ERBB2/MET</i> amplification should also be considered, as these are similarly known to confer resistance to EGFR blockade, although at lower prevalence in mCRC<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Sartore-Bianchi, A. et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 24, 1395‚Äì1402 (2019)." href="/articles/s41591-022-01886-0#ref-CR29" id="ref-link-section-d73924273e2062">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851‚Äì1857 (2009)." href="#ref-CR34" id="ref-link-section-d73924273e2065">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Cremolini, C. et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case‚Äìcontrol study. Ann. Oncol. 28, 3009‚Äì3014 (2017)." href="#ref-CR35" id="ref-link-section-d73924273e2065_1">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658‚Äì673 (2013)." href="#ref-CR36" id="ref-link-section-d73924273e2065_2">36</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat. Med. 25, 1415‚Äì1421 (2019)." href="#ref-CR37" id="ref-link-section-d73924273e2065_3">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Russo, M. et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 6, 147‚Äì153 (2016)." href="#ref-CR38" id="ref-link-section-d73924273e2065_4">38</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Siena, S. et al. Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). Ann. Oncol. 32, S530‚ÄìS582 (2021)." href="/articles/s41591-022-01886-0#ref-CR39" id="ref-link-section-d73924273e2068">39</a></sup>. Second, the assessment of anti-EGFR resistance-conferring mutations on ctDNA requires a dedicated ctDNA analysis laboratory support. As liquid biopsies become more routinely deployed, this issue should progressively fade owing to the large number of certified laboratories that now offer rapid ctDNA testing<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Downing, A. et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut 66, 89‚Äì96 (2017)." href="/articles/s41591-022-01886-0#ref-CR40" id="ref-link-section-d73924273e2072">40</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Ignatiadis, M., Sledge, G. W. &amp; Jeffrey, S. S. Liquid biopsy enters the clinic‚Äîimplementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297‚Äì312 (2021)." href="/articles/s41591-022-01886-0#ref-CR41" id="ref-link-section-d73924273e2075">41</a></sup>. Third, we are unable to precisely estimate whether stochastic mutational events could have affected the sensitivity of detecting variants by ddPCR or NGS. Fourth, despite the use of ctDNA-based selection, a formal comparison between retreatment versus later-line standard options is lacking despite the historically favorable results of the former. Although these results are addressed by ongoing trials<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Moretto, R. et al. Rationale and study design of the PARERE trial: randomized phase ii study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients. Clin. Colorectal Cancer 20, 314‚Äì317 (2021)." href="/articles/s41591-022-01886-0#ref-CR42" id="ref-link-section-d73924273e2079">42</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Strickler, J. H. et al. PULSE: a randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). J. Clin. Oncol. 
                  https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143
                  
                 (2021)." href="/articles/s41591-022-01886-0#ref-CR43" id="ref-link-section-d73924273e2082">43</a></sup>, considering that the activity and safety of panitumumab rechallenge favorably compares (especially regarding tumor shrinkage potential) with other standard-of-care therapies beyond the second line of treatment, the CHRONOS strategy could be readily deployed in the clinical setting<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909‚Äì1919 (2015)." href="/articles/s41591-022-01886-0#ref-CR14" id="ref-link-section-d73924273e2087">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303‚Äì312 (2013)." href="/articles/s41591-022-01886-0#ref-CR15" id="ref-link-section-d73924273e2090">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Modest, D. P., Pant, S. &amp; Sartore-Bianchi, A. Treatment sequencing in metastatic colorectal cancer. Eur. J. Cancer109, 70‚Äì83 (2019)." href="/articles/s41591-022-01886-0#ref-CR27" id="ref-link-section-d73924273e2093">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Argiles, G., Arnold, D., Prager, G., Sobrero, A. F. &amp; Van Cutsem, E. Maximising clinical benefit with adequate patient management beyond the second line in mCRC. ESMO Open 4, e000495 (2019)." href="/articles/s41591-022-01886-0#ref-CR30" id="ref-link-section-d73924273e2096">30</a></sup>.</p><p>In summary, CHRONOS demonstrated (to our knowledge for the first time prospectively) that genotyping tumor DNA in the blood can be safely, effectively and conveniently incorporated in the management of patients with mCRC. We conclude that ctDNA analysis is an effective strategy to select patients with mCRC for panitumumab rechallenge by allowing the maximization of treatment efficacy and concomitantly sparing iatrogenic toxicities.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec9-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec9">Methods</h2><div class="c-article-section__content" id="Sec9-content"><h3 class="c-article__sub-heading" id="Sec10">Study design</h3><p>CHRONOS (EudraCT 2016-002597-12, <a href="https://clinicaltrials.gov/ct2/show/NCT03227926">NCT03227926</a>) is an open-label, single-arm, multicenter, phase 2 trial designed to evaluate the efficacy of rechallenging with panitumumab a population of patients with <i>RAS/BRAF</i> WT mCRC selected on the basis of absence of <i>RAS</i>, <i>BRAF</i> and <i>EGFR</i> ECD resistance mutations in ctDNA at the actual moment of treatment initiation (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig1">1</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig5">1</a>). The primary endpoint was ORR by RECIST version 1.1 with independent central review. Secondary endpoints were PFS, OS, safety and tolerability of panitumumab rechallenge.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec11">Patient population</h4><p>The main inclusion criteria were histologically confirmed mCRC with <i>RAS</i> and <i>BRAF</i> WT status of the primary colorectal cancer and/or related metastasis; objective response and subsequent documented progression upon a previous anti-EGFR-therapy-based regimen administered in any line of treatment; intervening anti-EGFR-free treatment; and selection on the basis of <i>RAS</i>, <i>BRAF</i> and <i>EGFR</i> ECD WT status in ctDNA at molecular screening after progression (within 4‚Äâweeks) to the last anti-EGFR-free regimen (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig6">2</a>). Further criteria were age older than 18‚Äâyears; Eastern Cooperative Oncology Group (ECOG) performance status score of 0‚Äì2; and measurable metastatic disease according to RECIST version 1.1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228‚Äì247 (2009)." href="/articles/s41591-022-01886-0#ref-CR25" id="ref-link-section-d73924273e2167">25</a></sup>). The trial was conducted in accordance with the Declaration of Helsinki<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191‚Äì2194 (2013)." href="/articles/s41591-022-01886-0#ref-CR44" id="ref-link-section-d73924273e2171">44</a></sup> and adhered to international Good Clinical Practice guidelines. The protocol was approved by the local ethics committees of participating sites (Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Veneto Institute of Oncology (IOV)-IRCCS, Padua, Italy; Istituto di Candiolo, Fondazione del Piemonte per l‚ÄôOncologia, FPO-IRCCS, Candiolo, Italy; Policlinico Universitario Biomedico, Rome, Italy; HUMANITAS Research Hospital, Milan, Italy). All patients provided written informed consent to study procedures. For more details, see the full protocol detailed in Supplementary Material Appendix <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">1</a>. Due to the outbreak of the Coronavirus Disease 2019 (COVID-19) pandemic, and the resulting travel restrictions established by the Italian government, in three patients treatment was partially delivered in a hospital different from the initial recruiting center. Finally, some patients were enrolled following protocol violations as detailed in Supplementary Material Appendices <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">2</a>, <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">3</a> and <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">4</a>.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec12">Treatment and procedures</h4><p>Panitumumab was given at 6‚Äâmg‚Äâkg<sup>‚àí1</sup> by intravenous administration over 1‚Äâhour on day 1 every 2‚Äâweeks until disease progression. Dose was reduced or delayed in case of side effects according to the Panitumumab Summary of Product characteristics, as reported in the protocol (Supplementary Material Appendix <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">1</a>). A liquid biopsy was collected on days ‚àí28 to 0 to define the eligibility to the rechallenge treatment. Subsequently, liquid biopsies were drawn at each cycle until progression. Tumor assessments were performed by local radiologists within 4‚Äâweeks before treatment start (baseline) and were repeated every 8‚Äâweeks according to RECIST version 1.1 thereafter until progression. Local tumor assessments were reviewed centrally by two radiologists (D.R. and A.V.) who read the computed tomography scans blinded using Telemis version 4.9 software to collect, store and guide the revision of the imaging results. The imaging review protocol and tumor assessment reconciliation report are included in Supplementary Material Appendix <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">5</a>. Safety was continuously assessed and graded according to CTCAE version 4.03. (Protocol Supplementary Material Appendix <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">1</a>). All patients provided written informed consent. Detailed inclusion and exclusion criteria are provided in Supplementary Material Appendix <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">3</a>.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec13">Statistical analysis and reproducibility</h4><p>We used the A‚ÄôHern one-stage approach to calculate the sample size. For the primary objective of the trial, 27 patients were required to achieve a power of at least 85% to test the null hypothesis that the rate of response to panitumumab would be 10% or less versus the alternative hypothesis that the response rate would be 30% or more, at a one-sided alpha level of 0.05. Six objective responses were necessary to declare the study positive. Initially, only patients experiencing a ‚â•50% drop of <i>RAS/BRAF</i> plasma clones, determined by testing the ctDNA at prior anti-EGFR progression and at progression to the preceding chemotherapy, entered the trial. These screening criteria were rapidly modified due to logistics attrition and more recent retrospective clinical knowledge<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795‚Äì801 (2015)." href="/articles/s41591-022-01886-0#ref-CR9" id="ref-link-section-d73924273e2221">9</a></sup>, as discussed in detail above (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01886-0#Sec8">Discussion</a>). Accordingly, the protocol was amended to require a single determination of <i>RAS/RAF</i> and <i>EGFR</i> ECD WT ctDNA (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01886-0#Fig6">2</a>), obtained at progression of the immediately preceding chemotherapy (any type). However, the expected panitumumab rechallenge ORR remained the same‚Äîthat is, 30%‚Äîrequiring under the same alpha and beta assumption a sample size of 27 patients. Therefore, 27 patients were recruited in the amended protocol (version 3.0) and are here reported in both the safety and efficacy analyses. The five patients enrolled in the previous version of the protocol are not included in this analysis and will be reported separately.</p><p>Secondary endpoints were PFS and OS as well as safety, given that panitumumab is routinely administered to patients with CRC. Translational exploratory objectives were aimed at studying the molecular determinants of response and resistance to study treatment and included molecular characterization of longitudinal liquid biopsies collected during the treatment. Time-to-event variables were estimated using the Kaplan‚ÄìMeier method, and the log-rank test was used for testing the null hypothesis of no difference among curves. Analyses were performed with SAS statistical software, version 9.4.</p><p>No data were excluded from the analyses. The trial was not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec14">Plasma sample collection</h4><p>At least 10‚Äâml of whole blood was collected by blood draw using EDTA as anticoagulant. Plasma was separated within 5‚Äâhours through two different centrifugation steps (the first at room temperature for 10‚Äâminutes at 1,600<i>g</i> and the second at 3,000<i>g</i> for the same time and temperature), obtaining up to 3‚Äâml of plasma. Plasma was stored at ‚àí80‚Äâ¬∞C until ctDNA extraction.</p><h3 class="c-article__sub-heading" id="Sec15">ddPCR analysis of ctDNA</h3><p>cfDNA extracted from at least 4‚Äâml of plasma was amplified using ddPCR Supermix for Probes (Bio-Rad) using <i>KRAS G12/G13</i> (1863506), <i>NRAS G12</i> (12001094), <i>KRAS Q61</i> (12001626) and <i>NRAS Q61</i> (12001006) ddPCR Multiplex Mutation Screening Kit, <i>BRAF V600E</i> (dHsaMDV2010027) and <i>NRAS G13D</i> (dHsaMDV2510526) single-plex assay (Bio-Rad) and <i>EGFR</i> ECD custom design probes (Bio-Rad). ddPCR was then performed according to the manufacturer‚Äôs protocol, and the results were reported as the percentage or fractional abundance of mutant DNA alleles to total (mutant plus WT) DNA alleles. The theorical ddPCR limit of detection is one mutant in 20,000 WT molecules<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604‚Äì8610 (2011)." href="/articles/s41591-022-01886-0#ref-CR45" id="ref-link-section-d73924273e2290">45</a></sup>. Notably, in blood samples, the detection of mutant molecules is also affected by the quality of the starting material. To increase the sensitivity of each experiment, cfDNA was isolated from at least 4‚Äâml of plasma, and we considered unsuitable samples with fewer than 100 total ddPCR events. Next, 5‚Äì10‚ÄâŒºl of DNA template was added to 10‚ÄâŒºl of ddPCR Supermix for Probes (Bio-Rad) and 2‚ÄâŒºl of the primer and probe mixture. Droplets were generated using the Automated Droplet Generator (Bio-Rad) where the reaction mix was added together with Droplet Generation Oil for Probes (Bio-Rad). Droplets were then transferred to a 96-well plate and then thermal-cycled with the following conditions: 10‚Äâminutes at 95‚Äâ¬∞C, 40 cycles of 94‚Äâ¬∞C for 30‚Äâseconds, 55‚Äâ¬∞C for 1‚Äâminute, followed by 98‚Äâ¬∞C for 10‚Äâminutes (ramp rate 2‚Äâ¬∞C‚Äâs<sup>‚àí1</sup>). Droplets were analyzed with the QX200 Droplet Reader (Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was performed based on positive and negative controls, and mutant populations were identified. ddPCR data were analyzed with QuantaSoft analysis software (Bio-Rad) to obtain fractional abundance (F.A.) of the mutated or amplified DNA alleles in the WT or normal background. The quantification of the target molecule was presented as number of total copies (mutant plus WT) per sample in each reaction. F.A. is calculated as follows: F.A. % = (Nmut/(Nmut + Nwt) √ó 100), where Nmut is the number of mutant events, and Nwt is the number of WT events per reaction. Samples that showed positive events in the multiplex kit were afterwards tested for each single assay detected by the kit (<i>KRAS G12A</i>, <i>G12C</i>, <i>G12D</i>, <i>G12R</i>, <i>G12S</i>, <i>G12V</i> and <i>G13D</i>; <i>NRAS G12A</i>, <i>G12C</i>, <i>G12D</i>, <i>G12R</i>, <i>G12S</i> and <i>G12V</i>; and <i>KRAS</i> and <i>NRAS Q61H (183 A</i>&gt;<i>C)</i>, <i>Q61H (183 A</i>&gt;<i>T)</i>, <i>Q61K</i>, <i>Q61L</i> and <i>Q61R</i>). Each sample was analyzed in at least two technical replicates to validate the obtained results.</p><h3 class="c-article__sub-heading" id="Sec16">NGS workflow and data generation on ctDNA samples</h3><p>QIAmp MinElute ccfDNA Mini Kit (QIAGEN) was used for cfDNA extraction from plasma samples following the manufacturer‚Äôs protocol. Quantity and quality of cfDNA were evaluated by the Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific) and 2100 Bioanalyzer with a High-Sensitivity DNA Assay Kit (Agilent Technologies), respectively.</p><p>Library preparation methods optimized for analysis of small targets and for identification of very low allelic frequency variations were applied. In particular, starting from published methods for the DS approach<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586‚Äì2606 (2014)." href="/articles/s41591-022-01886-0#ref-CR46" id="ref-link-section-d73924273e2374">46</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508‚Äì14513 (2012)." href="/articles/s41591-022-01886-0#ref-CR47" id="ref-link-section-d73924273e2377">47</a></sup>, the protocol was specifically customized for cfDNA processing. Overall, based on the quality (highly fragmented) and the low quantity of starting material (from 35‚Äâng up to 100‚Äâng of input cfDNA), library preparation was performed with specific adjustments, whereas the target enrichment was customized with the design of a small target panel.</p><p>Library preparation started directly with end-repair reaction by using NEBNext End Repair Module (New England Biolabs) following the manufacturer‚Äôs protocol, therefore avoiding any fragmentation step. To minimize the loss of so short fragments (167‚Äì170‚Äâbase pairs (bp))<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795‚Äì801 (2015)." href="/articles/s41591-022-01886-0#ref-CR9" id="ref-link-section-d73924273e2384">9</a></sup> of low-input cfDNA, a clean-up step with an optimized ratio volume of AMPure XP beads (Beckman Coulter) was performed, without size selection. Furthermore, all clean-up washes foreseen in the workflow were performed maintaining samples/beads complex in the magnetic plate and using room temperature 80% (vol/vol) ethanol. For the subsequent dA-tailing reaction of blunt-ended DNA fragments, NEBNext dA-Tailing Module (New England Biolabs) was used, followed, again, by an optimized clean-up with AMPure XP beads (Beckman Coulter). At this point, quality and quantity for each sample were evaluated with 2100 Bioanalyzer with a High-Sensitivity DNA Assay Kit (Agilent Technologies). By using the so-obtained molarity for each cfDNA sample, the needed volume of DS adapters (for sequences and synthesis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586‚Äì2606 (2014)." href="/articles/s41591-022-01886-0#ref-CR46" id="ref-link-section-d73924273e2388">46</a></sup>) was calculated, considering an optimized ratio of 10:1 molar excess of DS adapters with respect to cfDNA. DS adapter ligation occurred with the use of T4 DNA Ligase Rapid Enzyme (600,000‚ÄâU‚Äâml<sup>‚àí1</sup>, Qiagen) with a longer incubation time with respect to the manufacturer‚Äôs instructions. The following AMPure XP beads-based clean-up step was improved to capture all DS adapter/cfDNA-ligated fragments and to wash out free adapters. DNA libraries, eluted in 1√ó TE Buffer Low EDTA (Affymetrix), were then evaluated by means of 2100 Bioanalyzer with a High-Sensitivity DNA Assay Kit (Agilent Technologies) to verify the proper ligation of DS adapters and to calculate the molarity of fragments of interest. At this point, because we updated the DS workflow for cfDNA processing, the yield we usually obtained in terms of attomoles was extremely lower than that suggested by the authors as necessary for proceeding<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586‚Äì2606 (2014)." href="/articles/s41591-022-01886-0#ref-CR46" id="ref-link-section-d73924273e2394">46</a></sup> on the bases of the target size of our custom panel. Therefore, the following step of PCR amplification for Duplex families generation was implemented, increasing the number of parallel reactions (ranging from four to six) and the number of PCR cycles (ranging from nine to 12), to obtain the best possible balance between the number of Duplex consensus families members and the total yield of amplified libraries. Duplicate families were obtained by using KAPA HotStart PCR Kit (250‚ÄâU, Roche) and primers specific for the DS approach (for all oligo sequences<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586‚Äì2606 (2014)." href="/articles/s41591-022-01886-0#ref-CR46" id="ref-link-section-d73924273e2398">46</a></sup>). The clean-up step was improved also in that case and was performed on pooled PCRs for each sample.</p><p>The target of interest was defined starting from the identification of genes (or specific exons) relevant for tumorigenesis, evolution and emergence of drug resistance in CRC. In detail, the genomic size of high-sensitivity capture LB panel (Liquid Biopsy panel, xGen Lockdown Probe Pools, IDT) is 59‚Äâkilobases for a total of 300 captured regions. The design includes hotspot regions of 44 target genes and all coding sequences of all isoforms of nine clinically relevant genes: <i>APC</i>, <i>BRAF</i>, <i>ERBB2</i>, <i>MET</i>, <i>TP53</i> and DNA damage response pathway genes (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>B2M</i> and <i>PMS2</i>). Moreover, tandem repeat sequences (ten loci) useful to determine the stability of microsatellite regions (MSS/MSI status) are included. Finally, the LB panel is embellished by a list of 55 single-nucleotide polymorphisms (SNPs) that were used to identify the allelic profile and to build the SNP identifier (SNP_ID) of each sample.</p><p>Before target enrichment and capture steps, fragment distribution patterns of post-family-PCR libraries were checked by means of 2100 Bioanalyzer with a High-Sensitivity DNA Assay Kit (Agilent Technologies), thus obtaining their concentration. Depending on the available material, a minimum of 1‚Äâ¬µg (up to 3‚Äâ¬µg) of post-PCR libraries was used for the LB panel target enrichment with xGen Hybridization and Wash Kit (Integrated DNA Technologies). The manufacturer‚Äôs protocol was followed, except for the choice to perform two rounds of enrichment/capture steps to increase the on-target capture. After the first round of target enrichment, a further amplification step was performed using the same primer oligos used for families PCR (for sequences, see ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209‚Äì249 (2021)." href="/articles/s41591-022-01886-0#ref-CR1" id="ref-link-section-d73924273e2440">1</a></sup>) and KAPA HiFi HotStart ReadyMix PCR Kit (Roche). All PCR-amplified material was then subjected to a second step of target enrichment/capture. A further amplification with KAPA HiFi HotStart ReadyMix PCR Kit (Roche) allowed reaching the amount required of final libraries and the insertion of individual index sequence (for sequences, see ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586‚Äì2606 (2014)." href="/articles/s41591-022-01886-0#ref-CR46" id="ref-link-section-d73924273e2444">46</a></sup>) needed for the demultiplexing of NGS data. Final libraries were quantified by means of Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific), and their fragment distribution was evaluated by the High-Sensitivity DNA Assay Kit (Agilent Technologies). Equal amounts of DNA libraries were pooled and sequenced using Illumina NextSeq 500 sequencer.</p><h3 class="c-article__sub-heading" id="Sec17">Bioinformatic workflow for ctDNA analysis</h3><p>All libraries were sequenced on NextSeq 500 sequencer (Illumina), and 150-bp paired-end READS were generated. The READS were processed using the described bioinformatic pipeline, which can be divided into five steps: (1) READS pre-processing; (2) tag parsing and initial alignment; (3) single-strand consensus sequence (SSCS) assembly; (4) duplex consensus sequencing (DCS) assembly; and (5) mutational calling. Points 2‚Äì4 were performed<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586‚Äì2606 (2014)." href="/articles/s41591-022-01886-0#ref-CR46" id="ref-link-section-d73924273e2456">46</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508‚Äì14513 (2012)." href="/articles/s41591-022-01886-0#ref-CR47" id="ref-link-section-d73924273e2459">47</a></sup> with the following customizations.</p><p>In the pre-processing step (1), to recover READS shorter than 150 bases, the READS length were checked, and, if necessary, ‚ÄòN‚Äô bases were added at the end to uniform the READ length to 150 bases. Mates with homopolimeric sequences longer than 35 nucleotides (nt) in the first 50 nucleotides were removed. As final pre-processed step (1), READS were sorted based on 12-nt tag sequence. Pre-processed READS, at the beginning of the second step (2), were composed by 12-nt tag sequence followed by invariant 5-bp nucleotides, which corresponds to the ligation site. This invariant 5-bp was used as anchor to recognize the variable sequence (12-nt tag). READS with homopolimeric sequences greater than 9 bases in the tag sequence and regions with mismatched nucleotides in 5-bp anchor sequence were discarded. The two 12-nt tags present on each of the two paired-end reads were merged into a single 24-nt tag that was used as new ‚Äòread name‚Äô in the read header<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586‚Äì2606 (2014)." href="/articles/s41591-022-01886-0#ref-CR46" id="ref-link-section-d73924273e2466">46</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508‚Äì14513 (2012)." href="/articles/s41591-022-01886-0#ref-CR47" id="ref-link-section-d73924273e2469">47</a></sup>. At the end of the process, the anchor sequence (the constant sequence of 5 bases at the beginning of the reads) was removed. In the third step (3), READS were aligned to the human genome reference version 19 (hg19) using BWA with standard option. READS sharing the same tag sequence and genomic coordinates were classified with a tag family (12-nt tag) and then grouped in a consensus (SSCS). In detail, a minimum of two members was required to build a tag family. The family members were then compared position by position (from the beginning to the end of each read), and the nucleotide was maintained in the SSCS only when at least 70% of the members were coherent. Genomic positions that could not form a consensus were considered undefined and replaced by an ‚ÄòN‚Äô base in the SSCS. A maximum of 30% ‚ÄòN‚Äô was permitted, and, if in a genomic position, more than 30% of the READS were ‚ÄòN‚Äô, in the SSCSs ‚ÄòN‚Äô base was reported. At the end of this step, two SSCSs (one for each strand) were created with tag Œ±Œ≤ (12‚Äâ+‚Äâ12 tag). (4) Two related SSCSs corresponding to the two initial DNA strands were grouped and compared position by position. Specifically, the two 12-nt sub-tag sequences Œ±‚Äâ+‚ÄâŒ≤ in the SSCS were associated with the complementary SSCS with tag Œ≤‚Äâ+‚ÄâŒ±<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586‚Äì2606 (2014)." href="/articles/s41591-022-01886-0#ref-CR46" id="ref-link-section-d73924273e2473">46</a></sup>. The 24-nt tag (Œ±‚Äâ+‚ÄâŒ≤) of the DCS was derived by the association of each paired SSCS consisting of two matched 12-nt sequences (Œ± and Œ≤) + (Œ≤ and Œ±). The tags of the matched SSCSs were grouped considering that each one corresponds to the transposed of the other. The paired-strand SSCSs were compared and only matching bases being kept producing the DCS. Non-matching bases were considered undefined and replaced by ‚ÄòN‚Äô in DCS. DCSs containing more than 30% of ‚ÄòN‚Äô were considered unsupported and discarded. In the last step (5), in order to all single-nucleotide variations, indels and copy number alterations, genetic discovery analysis was performed as previously reported<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Corti, G. et al. A genomic analysis workflow for colorectal cancer precision oncology. Clin. Colorectal Cancer 18, 91‚Äì101 (2019)." href="/articles/s41591-022-01886-0#ref-CR48" id="ref-link-section-d73924273e2477">48</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Crisafulli, G. et al. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO Open 4, e000572 (2019)." href="/articles/s41591-022-01886-0#ref-CR49" id="ref-link-section-d73924273e2480">49</a></sup>. Therefore, DCSs were mapped to hg19 using the BWA-mem algorithm with standard parameters. DCSs having more than seven mismatches compared to the human reference genome and bases with phred score &lt;30 were filtered out. Mutations supported by only mismatch in the head/tail of the DCSs were discarded, and only mutations supported by more than two DCSs with minimum 3√ó depth (using three different DCSs) were considered in the final analysis. Pindel tool was used to call the short indel using DCSs. Indels supported by fewer than three altered DCSs were filtered out. Tumor focal gene copy number variations (CNVs) were calculated as the ratio of the median depth of the probe region and the median depth of all chromosomal regions in the panel. Copy number was considered increased when the log<sub>2</sub> value was higher than 1 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Corti, G. et al. A genomic analysis workflow for colorectal cancer precision oncology. Clin. Colorectal Cancer 18, 91‚Äì101 (2019)." href="/articles/s41591-022-01886-0#ref-CR48" id="ref-link-section-d73924273e2486">48</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Crisafulli, G. et al. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO Open 4, e000572 (2019)." href="/articles/s41591-022-01886-0#ref-CR49" id="ref-link-section-d73924273e2489">49</a></sup>).</p><h3 class="c-article__sub-heading" id="Sec18">NGS workflow and data generation on archival samples</h3><p>Hematoxylin and eosin sections were cut from FFPE tumor blocks corresponding to a tumoral lesion of the 27 patients subjected to panitumumab rechallenge. These were archival samples collected before trial enrollment. In nine patients, the available lesion was collected after a prior anti-EGFR-containing regimen because samples used for eligibility to anti-EGFR prescription, as detailed in inclusion criterion 9, were not available due to tissue exhaustion for diagnostic procedures. For samples with adequate tumor cell content (26/27), four 8-¬µm-thick sections were microdissected, and DNA was extracted with the GeneRead DNA FFPE Kit (QIAGEN) and quantified with a fluorometric assay (Qubit, Thermo Fisher Scientific).</p><p>The OCAv3 target gene panel (161 genes) was applied to the available DNA purified from tumor FFPE samples. A total of 40‚Äâng of DNA was subjected to library preparation using the Ion AmpliSeq Library kit Plus (Thermo Fisher Scientific) following the manufacturer‚Äôs instructions. Ion Xpress Barcode and Ion P1 Adapter (Thermo Fisher Scientific) were inserted during the library preparation. The amplicon-based libraries were quantified using the Ion Library TaqMan Quantitation Kit (Thermo Fisher Scientific), diluted to 50‚ÄâpM and then sequenced. Template generation and chip loading were performed with the Ion Chef System (Thermo Fisher Scientific) by using the Ion 540 Kit-Chef, loaded to the Ion GeneStudioTM S5 Plus System for the sequencing (Thermo Fisher Scientific) for an expected mean read depth of 1,000√ó. BAM files derived from processed raw data were generated by the Ion Torrent platform-specific pipeline software (Torrent Suite Software 5.12, Thermo Fisher Scientific). All the BAM files were transferred on the Ion Reporter Software (version 5.10.5.0) (Thermo Fisher Scientific) and analyzed by the Oncomine OCAv3 w3.0‚ÄìDNA‚ÄìSingle Sample (version. 5.10). The Ion Reporter workflow was applied to identify SNVs, indels and CNVs with a tumor-only pipeline using the parameters and the Boolean chain reported in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">3</a>. Only those genes present also in the liquid biopsy panel were considered for downstream data analysis.</p><h3 class="c-article__sub-heading" id="Sec19">Reporting summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM2">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>The following information and data are available:</p>
              <p>1. Protocol: available in Supplementary Material Appendix <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">1</a>.</p>
              <p>2. Centralized peer revision of response: available in Supplementary Material Appendix <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01886-0#MOESM1">5</a>.</p>
              <p>3. Human sequencing data: fully anonymized data are available at the European Nucleotide Archive: <a href="https://www.ebi.ac.uk/ena/browser/home">https://www.ebi.ac.uk/ena/browser/home</a>, code <a href="https://www.ncbi.nlm.nih.gov/bioproject/840268">PRJEB49484</a>.</p>
              <p>4. Individual clinical data: Patient-related data not included in the manuscript and in the supplementary figures and materials were generated as part of a clinical trial and are subject to patient confidentiality according to the General Data Protection Regulation (2016/679).</p>
              <p>5. Other raw data: Requests for data and materials other than the clinical data above and that can be shared (for example, tissue samples or imaging data) will need approval from the institutional review board of Fondazione del Piemonte per l‚ÄôOncologia FPO-IRCCS and should be addressed to Fondazione del Piemonte per l‚ÄôOncologia FPO-IRCCS, Strada Provinciale, 142 -KM 3.95 - 10060 Candiolo ‚Äì Turin, Italy. All data shared will be de-identified.</p>
            </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J. Clin.</i> <b>71</b>, 209‚Äì249 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3322/caac.21660" data-track-item_id="10.3322/caac.21660" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3322%2Fcaac.21660" aria-label="Article reference 1" data-doi="10.3322/caac.21660">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33538338" aria-label="PubMed reference 1">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Global%20cancer%20statistics%202020%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;journal=CA%20Cancer%20J.%20Clin.&amp;doi=10.3322%2Fcaac.21660&amp;volume=71&amp;pages=209-249&amp;publication_year=2021&amp;author=Sung%2CH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Siegel, R. L., Miller, K. D., Fuchs, H. E. &amp; Jemal, A. Cancer statistics, 2021. <i>CA Cancer J. Clin.</i> <b>71</b>, 7‚Äì33 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3322/caac.21654" data-track-item_id="10.3322/caac.21654" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3322%2Fcaac.21654" aria-label="Article reference 2" data-doi="10.3322/caac.21654">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33433946" aria-label="PubMed reference 2">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Cancer%20statistics%2C%202021&amp;journal=CA%20Cancer%20J.%20Clin.&amp;doi=10.3322%2Fcaac.21654&amp;volume=71&amp;pages=7-33&amp;publication_year=2021&amp;author=Siegel%2CRL&amp;author=Miller%2CKD&amp;author=Fuchs%2CHE&amp;author=Jemal%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Di Nicolantonio, F. et al. Precision oncology in metastatic colorectal cancer‚Äîfrom biology to medicine. <i>Nat. Rev. Clin. Oncol.</i> <b>18</b>, 506‚Äì525 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41571-021-00495-z" data-track-item_id="10.1038/s41571-021-00495-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41571-021-00495-z" aria-label="Article reference 3" data-doi="10.1038/s41571-021-00495-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33864051" aria-label="PubMed reference 3">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlSjs7bE" aria-label="CAS reference 3">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Precision%20oncology%20in%20metastatic%20colorectal%20cancer%E2%80%94from%20biology%20to%20medicine&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-021-00495-z&amp;volume=18&amp;pages=506-525&amp;publication_year=2021&amp;author=Nicolantonio%2CF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Siravegna, G. &amp; Bardelli, A. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. <i>Mol. Oncol.</i> <b>10</b>, 475‚Äì480 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.molonc.2015.12.005" data-track-item_id="10.1016/j.molonc.2015.12.005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.molonc.2015.12.005" aria-label="Article reference 4" data-doi="10.1016/j.molonc.2015.12.005">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVGrt77E" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26774880" aria-label="PubMed reference 4">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Blood%20circulating%20tumor%20DNA%20for%20non-invasive%20genotyping%20of%20colon%20cancer%20patients&amp;journal=Mol.%20Oncol.&amp;doi=10.1016%2Fj.molonc.2015.12.005&amp;volume=10&amp;pages=475-480&amp;publication_year=2016&amp;author=Siravegna%2CG&amp;author=Bardelli%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Misale, S. et al. Emergence of <i>KRAS</i> mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> <b>486</b>, 532‚Äì536 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature11156" data-track-item_id="10.1038/nature11156" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature11156" aria-label="Article reference 5" data-doi="10.1038/nature11156">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XpsVSrsb4%3D" aria-label="CAS reference 5">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22722830" aria-label="PubMed reference 5">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927413" aria-label="PubMed Central reference 5">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Emergence%20of%20KRAS%20mutations%20and%20acquired%20resistance%20to%20anti-EGFR%20therapy%20in%20colorectal%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature11156&amp;volume=486&amp;pages=532-536&amp;publication_year=2012&amp;author=Misale%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. <i>Clin. Cancer Res</i> <b>21</b>, 2157‚Äì2166 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-14-2821" data-track-item_id="10.1158/1078-0432.CCR-14-2821" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-14-2821" aria-label="Article reference 6" data-doi="10.1158/1078-0432.CCR-14-2821">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXnvFaqs7k%3D" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25623215" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Emergence%20of%20multiple%20EGFR%20extracellular%20mutations%20during%20cetuximab%20treatment%20in%20colorectal%20cancer&amp;journal=Clin.%20Cancer%20Res&amp;doi=10.1158%2F1078-0432.CCR-14-2821&amp;volume=21&amp;pages=2157-2166&amp;publication_year=2015&amp;author=Arena%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Di Nicolantonio, F. et al. Wild-type <i>BRAF</i> is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <i>J. Clin. Oncol.</i> <b>26</b>, 5705‚Äì5712 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2008.18.0786" data-track-item_id="10.1200/JCO.2008.18.0786" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2008.18.0786" aria-label="Article reference 7" data-doi="10.1200/JCO.2008.18.0786">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19001320" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1MXotFemsA%3D%3D" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Wild-type%20BRAF%20is%20required%20for%20response%20to%20panitumumab%20or%20cetuximab%20in%20metastatic%20colorectal%20cancer&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2008.18.0786&amp;volume=26&amp;pages=5705-5712&amp;publication_year=2008&amp;author=Nicolantonio%2CF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Montagut, C. et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA Analyses: a phase 2 randomized clinical trial. <i>JAMA Oncol.</i> <b>4</b>, e175245 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jamaoncol.2017.5245" data-track-item_id="10.1001/jamaoncol.2017.5245" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaoncol.2017.5245" aria-label="Article reference 8" data-doi="10.1001/jamaoncol.2017.5245">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29423521" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885274" aria-label="PubMed Central reference 8">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20Sym004%20in%20patients%20with%20metastatic%20colorectal%20cancer%20with%20acquired%20resistance%20to%20anti-EGFR%20therapy%20and%20molecularly%20selected%20by%20circulating%20tumor%20DNA%20Analyses%3A%20a%20phase%202%20randomized%20clinical%20trial&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2017.5245&amp;volume=4&amp;publication_year=2018&amp;author=Montagut%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nat. Med.</i> <b>21</b>, 795‚Äì801 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nm.3870" data-track-item_id="10.1038/nm.3870" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnm.3870" aria-label="Article reference 9" data-doi="10.1038/nm.3870">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFeisrrI" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26030179" aria-label="PubMed reference 9">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868598" aria-label="PubMed Central reference 9">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Clonal%20evolution%20and%20resistance%20to%20EGFR%20blockade%20in%20the%20blood%20of%20colorectal%20cancer%20patients&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm.3870&amp;volume=21&amp;pages=795-801&amp;publication_year=2015&amp;author=Siravegna%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. <i>Ann. Oncol.</i> <b>26</b>, 731‚Äì736 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdv005" data-track-item_id="10.1093/annonc/mdv005" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdv005" aria-label="Article reference 10" data-doi="10.1093/annonc/mdv005">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC2MrgsVyltQ%3D%3D" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25628445" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374387" aria-label="PubMed Central reference 10">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Characterizing%20the%20patterns%20of%20clonal%20selection%20in%20circulating%20tumor%20DNA%20from%20patients%20with%20colorectal%20cancer%20refractory%20to%20anti-EGFR%20treatment&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdv005&amp;volume=26&amp;pages=731-736&amp;publication_year=2015&amp;author=Morelli%2CMP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Ann. Oncol.</i> <b>30</b>, 243‚Äì249 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdy509" data-track-item_id="10.1093/annonc/mdy509" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdy509" aria-label="Article reference 11" data-doi="10.1093/annonc/mdy509">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BB3crjtlOmuw%3D%3D" aria-label="CAS reference 11">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30462160" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Anti-EGFR-resistant%20clones%20decay%20exponentially%20after%20progression%3A%20implications%20for%20anti-EGFR%20re-challenge&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdy509&amp;volume=30&amp;pages=243-249&amp;publication_year=2019&amp;author=Parseghian%2CCM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Ann. Oncol.</i> <b>29</b>, 119‚Äì126 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdx504" data-track-item_id="10.1093/annonc/mdx504" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdx504" aria-label="Article reference 12" data-doi="10.1093/annonc/mdx504">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC1M%2FitV2ltg%3D%3D" aria-label="CAS reference 12">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28945848" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Dynamic%20molecular%20analysis%20and%20clinical%20correlates%20of%20tumor%20evolution%20within%20a%20phase%20II%20trial%20of%20panitumumab-based%20therapy%20in%20metastatic%20colorectal%20cancer&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx504&amp;volume=29&amp;pages=119-126&amp;publication_year=2018&amp;author=Siena%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Siravegna, G., Marsoni, S., Siena, S. &amp; Bardelli, A. Integrating liquid biopsies into the management of cancer. <i>Nat. Rev. Clin. Oncol.</i> <b>14</b>, 531‚Äì548 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nrclinonc.2017.14" data-track-item_id="10.1038/nrclinonc.2017.14" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrclinonc.2017.14" aria-label="Article reference 13" data-doi="10.1038/nrclinonc.2017.14">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXkvVSns7g%3D" aria-label="CAS reference 13">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28252003" aria-label="PubMed reference 13">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Integrating%20liquid%20biopsies%20into%20the%20management%20of%20cancer&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fnrclinonc.2017.14&amp;volume=14&amp;pages=531-548&amp;publication_year=2017&amp;author=Siravegna%2CG&amp;author=Marsoni%2CS&amp;author=Siena%2CS&amp;author=Bardelli%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>N. Engl. J. Med.</i> <b>372</b>, 1909‚Äì1919 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1414325" data-track-item_id="10.1056/NEJMoa1414325" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1414325" aria-label="Article reference 14" data-doi="10.1056/NEJMoa1414325">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25970050" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%20trial%20of%20TAS-102%20for%20refractory%20metastatic%20colorectal%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1414325&amp;volume=372&amp;pages=1909-1919&amp;publication_year=2015&amp;author=Mayer%2CRJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> <b>381</b>, 303‚Äì312 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(12)61900-X" data-track-item_id="10.1016/S0140-6736(12)61900-X" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2812%2961900-X" aria-label="Article reference 15" data-doi="10.1016/S0140-6736(12)61900-X">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38Xhslarsr%2FE" aria-label="CAS reference 15">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23177514" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Regorafenib%20monotherapy%20for%20previously%20treated%20metastatic%20colorectal%20cancer%20%28CORRECT%29%3A%20an%20international%2C%20multicentre%2C%20randomised%2C%20placebo-controlled%2C%20phase%203%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2812%2961900-X&amp;volume=381&amp;pages=303-312&amp;publication_year=2013&amp;author=Grothey%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Siena, S., Marsoni, S. &amp; Sartore-Bianchi, A. Breaking barriers in HER2<sup>+</sup> cancers. <i>Cancer Cell</i> <b>38</b>, 317‚Äì319 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ccell.2020.07.012" data-track-item_id="10.1016/j.ccell.2020.07.012" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ccell.2020.07.012" aria-label="Article reference 16" data-doi="10.1016/j.ccell.2020.07.012">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslWqt7fJ" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32857948" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Breaking%20barriers%20in%20HER2%2B%20cancers&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2020.07.012&amp;volume=38&amp;pages=317-319&amp;publication_year=2020&amp;author=Siena%2CS&amp;author=Marsoni%2CS&amp;author=Sartore-Bianchi%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Amatu, A. et al. Tropomyosin receptor kinase (TRK) biology and the role of <i>NTRK</i> gene fusions in cancer. <i>Ann. Oncol.</i> <b>30</b>, viii5‚Äìviii15 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdz383" data-track-item_id="10.1093/annonc/mdz383" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdz383" aria-label="Article reference 17" data-doi="10.1093/annonc/mdz383">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BB3MfgtlShsA%3D%3D" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32223939" aria-label="PubMed reference 17">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859819" aria-label="PubMed Central reference 17">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Tropomyosin%20receptor%20kinase%20%28TRK%29%20biology%20and%20the%20role%20of%20NTRK%20gene%20fusions%20in%20cancer&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdz383&amp;volume=30&amp;pages=viii5-viii15&amp;publication_year=2019&amp;author=Amatu%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>J. Natl Compr. Cancer Netw.</i> <b>19</b>, 329‚Äì359 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.6004/jnccn.2021.0012" data-track-item_id="10.6004/jnccn.2021.0012" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.6004%2Fjnccn.2021.0012" aria-label="Article reference 18" data-doi="10.6004/jnccn.2021.0012">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Colon%20Cancer%2C%20Version%202.2021%2C%20NCCN%20Clinical%20Practice%20Guidelines%20in%20Oncology&amp;journal=J.%20Natl%20Compr.%20Cancer%20Netw.&amp;doi=10.6004%2Fjnccn.2021.0012&amp;volume=19&amp;pages=329-359&amp;publication_year=2021&amp;author=Benson%2CAB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Yoshino, T. et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Ann. Oncol.</i> <b>29</b>, 44‚Äì70 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdx738" data-track-item_id="10.1093/annonc/mdx738" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdx738" aria-label="Article reference 19" data-doi="10.1093/annonc/mdx738">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC1M3jtVanug%3D%3D" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29155929" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Pan-Asian%20adapted%20ESMO%20consensus%20guidelines%20for%20the%20management%20of%20patients%20with%20metastatic%20colorectal%20cancer%3A%20a%20JSMO-ESMO%20initiative%20endorsed%20by%20CSCO%2C%20KACO%2C%20MOS%2C%20SSO%20and%20TOS&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx738&amp;volume=29&amp;pages=44-70&amp;publication_year=2018&amp;author=Yoshino%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Mauri, G. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. <i>Cancer Treat. Rev.</i> <b>73</b>, 41‚Äì53 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ctrv.2018.12.006" data-track-item_id="10.1016/j.ctrv.2018.12.006" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ctrv.2018.12.006" aria-label="Article reference 20" data-doi="10.1016/j.ctrv.2018.12.006">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXkvVGlsA%3D%3D" aria-label="CAS reference 20">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30616224" aria-label="PubMed reference 20">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Retreatment%20with%20anti-EGFR%20monoclonal%20antibodies%20in%20metastatic%20colorectal%20cancer%3A%20systematic%20review%20of%20different%20strategies&amp;journal=Cancer%20Treat.%20Rev.&amp;doi=10.1016%2Fj.ctrv.2018.12.006&amp;volume=73&amp;pages=41-53&amp;publication_year=2019&amp;author=Mauri%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Mauri, G. et al. Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities. <i>Cancer Treat. Rev.</i> <b>91</b>, 102112 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ctrv.2020.102112" data-track-item_id="10.1016/j.ctrv.2020.102112" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ctrv.2020.102112" aria-label="Article reference 21" data-doi="10.1016/j.ctrv.2020.102112">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitFyisbvI" aria-label="CAS reference 21">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33091698" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Oxaliplatin%20retreatment%20in%20metastatic%20colorectal%20cancer%3A%20systematic%20review%20and%20future%20research%20opportunities&amp;journal=Cancer%20Treat.%20Rev.&amp;doi=10.1016%2Fj.ctrv.2020.102112&amp;volume=91&amp;publication_year=2020&amp;author=Mauri%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Cremolini, C. et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.<i>JAMA Oncol.</i> <b>5</b>, 343‚Äì350 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jamaoncol.2018.5080" data-track-item_id="10.1001/jamaoncol.2018.5080" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaoncol.2018.5080" aria-label="Article reference 22" data-doi="10.1001/jamaoncol.2018.5080">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30476968" aria-label="PubMed reference 22">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Rechallenge%20for%20patients%20With%20RAS%20and%20BRAF%20wild-type%20metastatic%20colorectal%20cancer%20with%20acquired%20resistance%20to%20first-line%20cetuximab%20and%20irinotecan%3A%20a%20phase%202%20single-arm%20clinical%20trial.&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2018.5080&amp;volume=5&amp;pages=343-350&amp;publication_year=2019&amp;author=Cremolini%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with <i>RAS</i> wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. <i>JAMA Oncol.</i> <b>7</b>, 1529‚Äì1535 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jamaoncol.2021.2915" data-track-item_id="10.1001/jamaoncol.2021.2915" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaoncol.2021.2915" aria-label="Article reference 23" data-doi="10.1001/jamaoncol.2021.2915">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34382998" aria-label="PubMed reference 23">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Cetuximab%20rechallenge%20plus%20avelumab%20in%20pretreated%20patients%20with%20RAS%20wild-type%20metastatic%20colorectal%20cancer%3A%20the%20phase%202%20single-arm%20clinical%20CAVE%20trial&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2021.2915&amp;volume=7&amp;pages=1529-1535&amp;publication_year=2021&amp;author=Martinelli%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Alix-Panabi√®res, C. The future of liquid biopsy. <i>Nature</i> <b>579</b>, S9 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/d41586-020-00844-5" data-track-item_id="10.1038/d41586-020-00844-5" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fd41586-020-00844-5" aria-label="Article reference 24" data-doi="10.1038/d41586-020-00844-5">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32214259" aria-label="PubMed reference 24">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXlslKmsbs%3D" aria-label="CAS reference 24">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20future%20of%20liquid%20biopsy&amp;journal=Nature&amp;doi=10.1038%2Fd41586-020-00844-5&amp;volume=579&amp;publication_year=2020&amp;author=Alix-Panabi%C3%A8res%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <i>Eur. J. Cancer</i> <b>45</b>, 228‚Äì247 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ejca.2008.10.026" data-track-item_id="10.1016/j.ejca.2008.10.026" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ejca.2008.10.026" aria-label="Article reference 25" data-doi="10.1016/j.ejca.2008.10.026">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D" aria-label="CAS reference 25">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19097774" aria-label="PubMed reference 25">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=New%20response%20evaluation%20criteria%20in%20solid%20tumours%3A%20revised%20RECIST%20guideline%20%28version%201.1%29&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;volume=45&amp;pages=228-247&amp;publication_year=2009&amp;author=Eisenhauer%2CEA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Ali, M. et al. Codon bias imposes a targetable limitation on <i>KRAS</i>-driven therapeutic resistance. <i>Nat. Commun.</i> <b>8</b>, 15617 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ncomms15617" data-track-item_id="10.1038/ncomms15617" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fncomms15617" aria-label="Article reference 26" data-doi="10.1038/ncomms15617">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28593995" aria-label="PubMed reference 26">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472712" aria-label="PubMed Central reference 26">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Codon%20bias%20imposes%20a%20targetable%20limitation%20on%20KRAS-driven%20therapeutic%20resistance&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms15617&amp;volume=8&amp;publication_year=2017&amp;author=Ali%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Modest, D. P., Pant, S. &amp; Sartore-Bianchi, A. Treatment sequencing in metastatic colorectal cancer. <i>Eur. J. Cancer</i><b>109</b>, 70‚Äì83 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ejca.2018.12.019" data-track-item_id="10.1016/j.ejca.2018.12.019" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ejca.2018.12.019" aria-label="Article reference 27" data-doi="10.1016/j.ejca.2018.12.019">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVaqu78%3D" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30690295" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Treatment%20sequencing%20in%20metastatic%20colorectal%20cancer&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2018.12.019&amp;volume=109&amp;pages=70-83&amp;publication_year=2019&amp;author=Modest%2CDP&amp;author=Pant%2CS&amp;author=Sartore-Bianchi%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Bertotti, A. et al. The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> <b>526</b>, 263‚Äì267 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature14969" data-track-item_id="10.1038/nature14969" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature14969" aria-label="Article reference 28" data-doi="10.1038/nature14969">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1Chu7jE" aria-label="CAS reference 28">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26416732" aria-label="PubMed reference 28">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878148" aria-label="PubMed Central reference 28">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20genomic%20landscape%20of%20response%20to%20EGFR%20blockade%20in%20colorectal%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature14969&amp;volume=526&amp;pages=263-267&amp;publication_year=2015&amp;author=Bertotti%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Sartore-Bianchi, A. et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. <i>Oncologist</i> <b>24</b>, 1395‚Äì1402 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1634/theoncologist.2018-0785" data-track-item_id="10.1634/theoncologist.2018-0785" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1634%2Ftheoncologist.2018-0785" aria-label="Article reference 29" data-doi="10.1634/theoncologist.2018-0785">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXkvVCrsLc%3D" aria-label="CAS reference 29">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30952821" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795149" aria-label="PubMed Central reference 29">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=HER2%20positivity%20predicts%20unresponsiveness%20to%20EGFR-targeted%20treatment%20in%20metastatic%20colorectal%20cancer&amp;journal=Oncologist&amp;doi=10.1634%2Ftheoncologist.2018-0785&amp;volume=24&amp;pages=1395-1402&amp;publication_year=2019&amp;author=Sartore-Bianchi%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Argiles, G., Arnold, D., Prager, G., Sobrero, A. F. &amp; Van Cutsem, E. Maximising clinical benefit with adequate patient management beyond the second line in mCRC. <i>ESMO Open</i> <b>4</b>, e000495 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1136/esmoopen-2019-000495" data-track-item_id="10.1136/esmoopen-2019-000495" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1136%2Fesmoopen-2019-000495" aria-label="Article reference 30" data-doi="10.1136/esmoopen-2019-000495">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31231561" aria-label="PubMed reference 30">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555611" aria-label="PubMed Central reference 30">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Maximising%20clinical%20benefit%20with%20adequate%20patient%20management%20beyond%20the%20second%20line%20in%20mCRC&amp;journal=ESMO%20Open&amp;doi=10.1136%2Fesmoopen-2019-000495&amp;volume=4&amp;publication_year=2019&amp;author=Argiles%2CG&amp;author=Arnold%2CD&amp;author=Prager%2CG&amp;author=Sobrero%2CAF&amp;author=Cutsem%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Rossini, D. et al. Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis. <i>Clin. Colorectal Cancer</i> <b>19</b>, 191‚Äì199 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.clcc.2020.03.009" data-track-item_id="10.1016/j.clcc.2020.03.009" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.clcc.2020.03.009" aria-label="Article reference 31" data-doi="10.1016/j.clcc.2020.03.009">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32466976" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Retreatment%20with%20anti-EGFR%20antibodies%20in%20metastatic%20colorectal%20cancer%20patients%3A%20a%20multi-institutional%20analysis&amp;journal=Clin.%20Colorectal%20Cancer&amp;doi=10.1016%2Fj.clcc.2020.03.009&amp;volume=19&amp;pages=191-199&amp;publication_year=2020&amp;author=Rossini%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Khan, K. H. et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. <i>Cancer Discov.</i> <b>8</b>, 1270‚Äì1285 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-17-0891" data-track-item_id="10.1158/2159-8290.CD-17-0891" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-17-0891" aria-label="Article reference 32" data-doi="10.1158/2159-8290.CD-17-0891">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXmt1ehsbg%3D" aria-label="CAS reference 32">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30166348" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380469" aria-label="PubMed Central reference 32">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Longitudinal%20liquid%20biopsy%20and%20mathematical%20modeling%20of%20clonal%20evolution%20forecast%20time%20to%20treatment%20failure%20in%20the%20PROSPECT-C%20phase%20II%20colorectal%20cancer%20clinical%20trial&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-17-0891&amp;volume=8&amp;pages=1270-1285&amp;publication_year=2018&amp;author=Khan%2CKH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Thierry, A. R. et al. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. <i>Clin. Cancer Res.</i> <b>23</b>, 4578‚Äì4591 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-17-0232" data-track-item_id="10.1158/1078-0432.CCR-17-0232" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-17-0232" aria-label="Article reference 33" data-doi="10.1158/1078-0432.CCR-17-0232">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlCmu7vJ" aria-label="CAS reference 33">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28400427" aria-label="PubMed reference 33">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562356" aria-label="PubMed Central reference 33">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Circulating%20DNA%20demonstrates%20convergent%20evolution%20and%20common%20resistance%20mechanisms%20during%20treatment%20of%20colorectal%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-17-0232&amp;volume=23&amp;pages=4578-4591&amp;publication_year=2017&amp;author=Thierry%2CAR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Sartore-Bianchi, A. et al. <i>PIK3CA</i> mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. <i>Cancer Res.</i> <b>69</b>, 1851‚Äì1857 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-08-2466" data-track-item_id="10.1158/0008-5472.CAN-08-2466" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-08-2466" aria-label="Article reference 34" data-doi="10.1158/0008-5472.CAN-08-2466">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1MXisFSrt7Y%3D" aria-label="CAS reference 34">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19223544" aria-label="PubMed reference 34">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=PIK3CA%20mutations%20in%20colorectal%20cancer%20are%20associated%20with%20clinical%20resistance%20to%20EGFR-targeted%20monoclonal%20antibodies&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-08-2466&amp;volume=69&amp;pages=1851-1857&amp;publication_year=2009&amp;author=Sartore-Bianchi%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Cremolini, C. et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case‚Äìcontrol study. <i>Ann. Oncol.</i> <b>28</b>, 3009‚Äì3014 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdx546" data-track-item_id="10.1093/annonc/mdx546" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdx546" aria-label="Article reference 35" data-doi="10.1093/annonc/mdx546">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC1M7itVCgtQ%3D%3D" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29045518" aria-label="PubMed reference 35">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Negative%20hyper-selection%20of%20metastatic%20colorectal%20cancer%20patients%20for%20anti-EGFR%20monoclonal%20antibodies%3A%20the%20PRESSING%20case%E2%80%93control%20study&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx546&amp;volume=28&amp;pages=3009-3014&amp;publication_year=2017&amp;author=Cremolini%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Bardelli, A. et al. Amplification of the <i>MET</i> receptor drives resistance to anti-EGFR therapies in colorectal cancer. <i>Cancer Discov.</i> <b>3</b>, 658‚Äì673 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-12-0558" data-track-item_id="10.1158/2159-8290.CD-12-0558" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-12-0558" aria-label="Article reference 36" data-doi="10.1158/2159-8290.CD-12-0558">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXptVOrt7Y%3D" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23729478" aria-label="PubMed reference 36">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078408" aria-label="PubMed Central reference 36">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Amplification%20of%20the%20MET%20receptor%20drives%20resistance%20to%20anti-EGFR%20therapies%20in%20colorectal%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-12-0558&amp;volume=3&amp;pages=658-673&amp;publication_year=2013&amp;author=Bardelli%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nat. Med.</i> <b>25</b>, 1415‚Äì1421 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-019-0561-9" data-track-item_id="10.1038/s41591-019-0561-9" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-019-0561-9" aria-label="Article reference 37" data-doi="10.1038/s41591-019-0561-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhslelurnJ" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31501609" aria-label="PubMed reference 37">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741444" aria-label="PubMed Central reference 37">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Liquid%20versus%20tissue%20biopsy%20for%20detecting%20acquired%20resistance%20and%20tumor%20heterogeneity%20in%20gastrointestinal%20cancers&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0561-9&amp;volume=25&amp;pages=1415-1421&amp;publication_year=2019&amp;author=Parikh%2CAR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Russo, M. et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. <i>Cancer Discov.</i> <b>6</b>, 147‚Äì153 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-15-1283" data-track-item_id="10.1158/2159-8290.CD-15-1283" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-15-1283" aria-label="Article reference 38" data-doi="10.1158/2159-8290.CD-15-1283">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XisVyjtL4%3D" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26644315" aria-label="PubMed reference 38">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20heterogeneity%20and%20lesion-specific%20response%20to%20targeted%20therapy%20in%20colorectal%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-15-1283&amp;volume=6&amp;pages=147-153&amp;publication_year=2016&amp;author=Russo%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Siena, S. et al. Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). <i>Ann. Oncol.</i> <b>32</b>, S530‚ÄìS582 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Exploratory%20biomarker%20analysis%20of%20DESTINY-CRC01%2C%20a%20phase%20II%2C%20multicenter%2C%20open-label%20study%20of%20trastuzumab%20deruxtecan%20%28T-DXd%2C%20DS-8201%29%20in%20patients%20%28pts%29%20with%20HER2-expressing%20metastatic%20colorectal%20cancer%20%28mCRC%29&amp;journal=Ann.%20Oncol.&amp;volume=32&amp;publication_year=2021&amp;author=Siena%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Downing, A. et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. <i>Gut</i> <b>66</b>, 89‚Äì96 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1136/gutjnl-2015-311308" data-track-item_id="10.1136/gutjnl-2015-311308" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1136%2Fgutjnl-2015-311308" aria-label="Article reference 40" data-doi="10.1136/gutjnl-2015-311308">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27797935" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=High%20hospital%20research%20participation%20and%20improved%20colorectal%20cancer%20survival%20outcomes%3A%20a%20population-based%20study&amp;journal=Gut&amp;doi=10.1136%2Fgutjnl-2015-311308&amp;volume=66&amp;pages=89-96&amp;publication_year=2017&amp;author=Downing%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Ignatiadis, M., Sledge, G. W. &amp; Jeffrey, S. S. Liquid biopsy enters the clinic‚Äîimplementation issues and future challenges. <i>Nat. Rev. Clin. Oncol.</i> <b>18</b>, 297‚Äì312 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41571-020-00457-x" data-track-item_id="10.1038/s41571-020-00457-x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41571-020-00457-x" aria-label="Article reference 41" data-doi="10.1038/s41571-020-00457-x">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33473219" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Liquid%20biopsy%20enters%20the%20clinic%E2%80%94implementation%20issues%20and%20future%20challenges&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-020-00457-x&amp;volume=18&amp;pages=297-312&amp;publication_year=2021&amp;author=Ignatiadis%2CM&amp;author=Sledge%2CGW&amp;author=Jeffrey%2CSS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Moretto, R. et al. Rationale and study design of the PARERE trial: randomized phase ii study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients. <i>Clin. Colorectal Cancer</i> <b>20</b>, 314‚Äì317 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.clcc.2021.07.001" data-track-item_id="10.1016/j.clcc.2021.07.001" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.clcc.2021.07.001" aria-label="Article reference 42" data-doi="10.1016/j.clcc.2021.07.001">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34364814" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Rationale%20and%20study%20design%20of%20the%20PARERE%20trial%3A%20randomized%20phase%20ii%20study%20of%20panitumumab%20re-treatment%20followed%20by%20regorafenib%20versus%20the%20reverse%20sequence%20in%20RAS%20and%20BRAF%20wild-type%20chemo-refractory%20metastatic%20colorectal%20cancer%20patients&amp;journal=Clin.%20Colorectal%20Cancer&amp;doi=10.1016%2Fj.clcc.2021.07.001&amp;volume=20&amp;pages=314-317&amp;publication_year=2021&amp;author=Moretto%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Strickler, J. H. et al. PULSE: a randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with <i>RAS</i> wild-type metastatic colorectal cancer (mCRC). <i>J. Clin. Oncol.</i> <a href="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143">https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143</a> (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. <i>JAMA</i> <b>310</b>, 2191‚Äì2194 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jama.2013.281053" data-track-item_id="10.1001/jama.2013.281053" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2013.281053" aria-label="Article reference 44" data-doi="10.1001/jama.2013.281053">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXmtVOmsA%3D%3D" aria-label="CAS reference 44">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=World%20Medical%20Association%20Declaration%20of%20Helsinki%3A%20ethical%20principles%20for%20medical%20research%20involving%20human%20subjects&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2013.281053&amp;volume=310&amp;pages=2191-2194&amp;publication_year=2013">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. <i>Anal. Chem.</i> <b>83</b>, 8604‚Äì8610 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1021/ac202028g" data-track-item_id="10.1021/ac202028g" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1021%2Fac202028g" aria-label="Article reference 45" data-doi="10.1021/ac202028g">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtlyhtLzL" aria-label="CAS reference 45">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22035192" aria-label="PubMed reference 45">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216358" aria-label="PubMed Central reference 45">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=High-throughput%20droplet%20digital%20PCR%20system%20for%20absolute%20quantitation%20of%20DNA%20copy%20number&amp;journal=Anal.%20Chem.&amp;doi=10.1021%2Fac202028g&amp;volume=83&amp;pages=8604-8610&amp;publication_year=2011&amp;author=Hindson%2CBJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. <i>Nat. Protoc.</i> <b>9</b>, 2586‚Äì2606 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nprot.2014.170" data-track-item_id="10.1038/nprot.2014.170" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnprot.2014.170" aria-label="Article reference 46" data-doi="10.1038/nprot.2014.170">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXhslaqs7jF" aria-label="CAS reference 46">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25299156" aria-label="PubMed reference 46">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271547" aria-label="PubMed Central reference 46">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Detecting%20ultralow-frequency%20mutations%20by%20Duplex%20Sequencing&amp;journal=Nat.%20Protoc.&amp;doi=10.1038%2Fnprot.2014.170&amp;volume=9&amp;pages=2586-2606&amp;publication_year=2014&amp;author=Kennedy%2CSR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. <i>Proc. Natl Acad. Sci. USA</i> <b>109</b>, 14508‚Äì14513 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1073/pnas.1208715109" data-track-item_id="10.1073/pnas.1208715109" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1073%2Fpnas.1208715109" aria-label="Article reference 47" data-doi="10.1073/pnas.1208715109">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhsVaqu77E" aria-label="CAS reference 47">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22853953" aria-label="PubMed reference 47">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437896" aria-label="PubMed Central reference 47">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Detection%20of%20ultra-rare%20mutations%20by%20next-generation%20sequencing&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1208715109&amp;volume=109&amp;pages=14508-14513&amp;publication_year=2012&amp;author=Schmitt%2CMW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Corti, G. et al. A genomic analysis workflow for colorectal cancer precision oncology. <i>Clin. Colorectal Cancer</i> <b>18</b>, 91‚Äì101 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.clcc.2019.02.008" data-track-item_id="10.1016/j.clcc.2019.02.008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.clcc.2019.02.008" aria-label="Article reference 48" data-doi="10.1016/j.clcc.2019.02.008">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30981604" aria-label="PubMed reference 48">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20genomic%20analysis%20workflow%20for%20colorectal%20cancer%20precision%20oncology&amp;journal=Clin.%20Colorectal%20Cancer&amp;doi=10.1016%2Fj.clcc.2019.02.008&amp;volume=18&amp;pages=91-101&amp;publication_year=2019&amp;author=Corti%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Crisafulli, G. et al. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> <b>4</b>, e000572 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1136/esmoopen-2019-000572" data-track-item_id="10.1136/esmoopen-2019-000572" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1136%2Fesmoopen-2019-000572" aria-label="Article reference 49" data-doi="10.1136/esmoopen-2019-000572">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32149725" aria-label="PubMed reference 49">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001107" aria-label="PubMed Central reference 49">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=Whole%20exome%20sequencing%20analysis%20of%20urine%20trans-renal%20tumour%20DNA%20in%20metastatic%20colorectal%20cancer%20patients&amp;journal=ESMO%20Open&amp;doi=10.1136%2Fesmoopen-2019-000572&amp;volume=4&amp;publication_year=2019&amp;author=Crisafulli%2CG">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01886-0?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>The research leading to these results received funding from: FONDAZIONE AIRC under 5 per Mille 2018 (ID 21091 program) (A.B., D.R., C.M., S.M. and S.S.); AIRC under IG 2018 (ID 21923 project) (A.B.); European Research Council under the European Union‚Äôs Horizon 2020 research and innovation programme (grant agreement no. 101020342) (A.B.); IMI contract no. 101007937 PERSIST-SEQ (A.B.); International Accelerator Award, ACRCelerate, jointly funded by Cancer Research UK (A26825 and A28223), FC AECC (GEACC18004TAB) and AIRC (22795) (A.B.); BiLiGeCT, Progetto PON ARS01_00492 (A.B.); Ministero della Salute, Ricerca Corrente 2021-2022; Fondazione Oncologia Niguarda ONLUS; and Amgen that donated panitumumab for clinical use. We thank the patients and their families, all caregivers and the referring oncologists.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="na1"><p>These authors contributed equally: Silvia Marsoni, Salvatore Siena, Alberto Bardelli.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Department of Oncology and Hemato-Oncology, Universit√† degli Studi di Milano (La Statale), Milan, Italy</p><p class="c-article-author-affiliation__authors-list">Andrea Sartore-Bianchi,&nbsp;Gianluca Mauri,&nbsp;Angelo Vanzulli&nbsp;&amp;&nbsp;Salvatore Siena</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy</p><p class="c-article-author-affiliation__authors-list">Andrea Sartore-Bianchi,&nbsp;Alessio Amatu,&nbsp;Federica Tosi&nbsp;&amp;&nbsp;Salvatore Siena</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy</p><p class="c-article-author-affiliation__authors-list">Filippo Pietrantonio,&nbsp;Paolo Manca&nbsp;&amp;&nbsp;Margherita Ambrosini</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy</p><p class="c-article-author-affiliation__authors-list">Sara Lonardi,&nbsp;Francesca Bergamo&nbsp;&amp;&nbsp;Francesca Daniel</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy</p><p class="c-article-author-affiliation__authors-list">Benedetta Mussolin,&nbsp;Francesco Rua,&nbsp;Giovanni Crisafulli,&nbsp;Alice Bartolini,&nbsp;Elisabetta Fenocchio,&nbsp;Caterina Marchi√≤,&nbsp;Enrico Berrino,&nbsp;Anna Sapino&nbsp;&amp;&nbsp;Alberto Bardelli</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Department of Oncology, University of Turin, Turin, Italy</p><p class="c-article-author-affiliation__authors-list">Giovanni Crisafulli&nbsp;&amp;&nbsp;Alberto Bardelli</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">IFOM, FIRC Institute of Molecular Oncology, Milan, Italy</p><p class="c-article-author-affiliation__authors-list">Gianluca Mauri&nbsp;&amp;&nbsp;Silvia Marsoni</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Mario Negri Institute for Pharmacological Research-IRCCS, Milan, Italy</p><p class="c-article-author-affiliation__authors-list">Valter Torri</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Department of Services, Grande Ospedale Metropolitano Niguarda, Milan, Italy</p><p class="c-article-author-affiliation__authors-list">Angelo Vanzulli</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Department of Surgical Sciences, University of Turin, Turin, Italy</p><p class="c-article-author-affiliation__authors-list">Daniele Regge</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy</p><p class="c-article-author-affiliation__authors-list">Daniele Regge&nbsp;&amp;&nbsp;Giovanni Cappello</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">Department of Medical Sciences, University of Turin, Turin, Italy</p><p class="c-article-author-affiliation__authors-list">Caterina Marchi√≤,&nbsp;Enrico Berrino&nbsp;&amp;&nbsp;Anna Sapino</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Andrea-Sartore_Bianchi-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Andrea Sartore-Bianchi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Andrea%20Sartore-Bianchi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Andrea%20Sartore-Bianchi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Andrea%20Sartore-Bianchi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Filippo-Pietrantonio-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Filippo Pietrantonio</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Filippo%20Pietrantonio" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Filippo%20Pietrantonio" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Filippo%20Pietrantonio%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sara-Lonardi-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Sara Lonardi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sara%20Lonardi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sara%20Lonardi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sara%20Lonardi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Benedetta-Mussolin-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Benedetta Mussolin</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Benedetta%20Mussolin" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Benedetta%20Mussolin" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Benedetta%20Mussolin%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Francesco-Rua-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Francesco Rua</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Francesco%20Rua" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Francesco%20Rua" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Francesco%20Rua%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Giovanni-Crisafulli-Aff5-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Giovanni Crisafulli</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Giovanni%20Crisafulli" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Giovanni%20Crisafulli" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Giovanni%20Crisafulli%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Alice-Bartolini-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Alice Bartolini</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Alice%20Bartolini" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Alice%20Bartolini" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Alice%20Bartolini%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Elisabetta-Fenocchio-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Elisabetta Fenocchio</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Elisabetta%20Fenocchio" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Elisabetta%20Fenocchio" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Elisabetta%20Fenocchio%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Alessio-Amatu-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Alessio Amatu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Alessio%20Amatu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Alessio%20Amatu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Alessio%20Amatu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Paolo-Manca-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Paolo Manca</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Paolo%20Manca" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Paolo%20Manca" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Paolo%20Manca%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Francesca-Bergamo-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Francesca Bergamo</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Francesca%20Bergamo" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Francesca%20Bergamo" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Francesca%20Bergamo%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Federica-Tosi-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Federica Tosi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Federica%20Tosi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Federica%20Tosi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Federica%20Tosi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Gianluca-Mauri-Aff1-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Gianluca Mauri</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Gianluca%20Mauri" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Gianluca%20Mauri" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Gianluca%20Mauri%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Margherita-Ambrosini-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Margherita Ambrosini</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Margherita%20Ambrosini" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Margherita%20Ambrosini" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Margherita%20Ambrosini%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Francesca-Daniel-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Francesca Daniel</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Francesca%20Daniel" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Francesca%20Daniel" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Francesca%20Daniel%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Valter-Torri-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Valter Torri</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Valter%20Torri" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Valter%20Torri" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Valter%20Torri%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Angelo-Vanzulli-Aff1-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Angelo Vanzulli</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Angelo%20Vanzulli" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Angelo%20Vanzulli" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Angelo%20Vanzulli%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Daniele-Regge-Aff10-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Daniele Regge</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Daniele%20Regge" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Daniele%20Regge" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Daniele%20Regge%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Giovanni-Cappello-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Giovanni Cappello</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Giovanni%20Cappello" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Giovanni%20Cappello" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Giovanni%20Cappello%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Caterina-Marchi_-Aff5-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Caterina Marchi√≤</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Caterina%20Marchi%C3%B2" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Caterina%20Marchi%C3%B2" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Caterina%20Marchi%C3%B2%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Enrico-Berrino-Aff5-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Enrico Berrino</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Enrico%20Berrino" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Enrico%20Berrino" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Enrico%20Berrino%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Anna-Sapino-Aff5-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Anna Sapino</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Anna%20Sapino" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Anna%20Sapino" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Anna%20Sapino%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Silvia-Marsoni-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Silvia Marsoni</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Silvia%20Marsoni" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Silvia%20Marsoni" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Silvia%20Marsoni%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Salvatore-Siena-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Salvatore Siena</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Salvatore%20Siena" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Salvatore%20Siena" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Salvatore%20Siena%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Alberto-Bardelli-Aff5-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Alberto Bardelli</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Alberto%20Bardelli" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Alberto%20Bardelli" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Alberto%20Bardelli%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>Conception and design of the trial: A.B., S.S., S.M. and A.S.-B. Financial support: A.B., S.S. and A.S. Clinical data collection and assembly: A.S.-B., F.P., S.L., E.F., A.A., F.R., P.M., F.B., F.T., G.M., M.A. and F.D. Statistical analysis: V.T. Radiological assessment and review: A.V., D.R. and G.C. Translational data collection and assembly, including blood and solid tumor tissue samples: F.R., G.M. and C.M. Translational data analysis and interpretation, including circulating tumor DNA and solid tumor tissue sample analysis: B.M., G.C., A.B., G.M., C.M. and E.B. Writing of the manuscript: A.S.-B., A.B., S.M., S.S., G.M. and F.R.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:alberto.bardelli@unito.it">Alberto Bardelli</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar4">Competing interests</h3>
                <p>A.S.-B. is an advisory board member for Amgen, Bayer, Novartis, Sanofi and Servier. F.P. received honoraria/speaker activity from Merck Serono, Amgen, Sanofi, Eli Lilly, Bayer, Servier, AstraZeneca, Merck Sharp &amp; Dohme and Organon and received research grants from Bristol-Myers Squibb and AstraZeneca. S.L. is an advisory board member for Amgen, Merck Serono, Eli Lilly, AstraZeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier and Merck Sharp &amp; Dohme and participated in Speakers‚Äô Bureau for Roche, Eli Lilly, Bristol-Myers Squibb, Servier, Merck Serono, Pierre-Fabre, GlaxoSmithKline and Amgen and received research funding from Amgen, Merck Serono, Bayer, Roche, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. A.A. is an advisory board member for Roche and Bayer and received honoraria from CheckmAb. C.M. received personal consultancy fees from Bayer, Roche, Daiichi-Sankyo and AstraZeneca. S.S. is an advisory board member for Agenus, AstraZeneca, Bayer, Bristol-Myers Squibb, CheckmAb, Daiichi-Sankyo, Guardant Health, Menarini, Merck, Novartis, Roche-Genentech and Seagen. A.B. is an advisory board member for NeoPhore and Inivata and a shareholder of NeoPhore and received research support from AstraZeneca and Boehringer Ingelheim. The remaining authors declare no competing interests.</p>
              
            </div></div></section><section data-title="Peer review"><div class="c-article-section" id="peer-review-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="peer-review">Peer review</h2><div class="c-article-section__content" id="peer-review-content">
              
              
                <h3 class="c-article__sub-heading" id="FPar3">Peer review information</h3>
                <p><i>Nature Medicine</i> thanks Ramon Salazar and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary handling editor: Joao Monteiro, in collaboration with the <i>Nature Medicine</i> team.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher‚Äôs note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec21-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec21">Extended data</h2><div class="c-article-section__content" id="Sec21-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig5"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 schematic representation of t" href="/articles/s41591-022-01886-0/figures/5" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig5_ESM.jpg">Extended Data Fig. 1 Schematic representation of the CHRONOS trial design (Amendment 3.0).</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Schematic representation of the CHRONOS trial design (Amendment 3.0). Created with BioRender.com.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 molecular screening panel bas" href="/articles/s41591-022-01886-0/figures/6" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig6_ESM.jpg">Extended Data Fig. 2 Molecular screening panel based on droplet-digital PCR implemented in the CHRONOS trial.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Molecular screening panel based on droplet-digital PCR implemented in the CHRONOS trial.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 outcome to panitumumab rechal" href="/articles/s41591-022-01886-0/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig7_ESM.jpg">Extended Data Fig. 3 Outcome to panitumumab rechallenge in CHRONOS trial, according to (right) RECIST 1.1 response and progression-free survival and (left) the number and type of previous lines of treatments, type of previous anti-EGFR agent administered, and primary tumor sidedness.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Outcome to panitumumab rechallenge in CHRONOS trial, according to (right) RECIST 1.1 response and progression-free survival and (left) the number and type of previous lines of treatments, type of previous anti-EGFR agent administered, and primary tumor sidedness. Created with GraphPad Prism 9.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 progression-free survival (pa" href="/articles/s41591-022-01886-0/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig8_ESM.jpg">Extended Data Fig. 4 Progression-free survival (panel A) and overall survival (panel B) of the 27 patients enrolled in the CHRONOS trial.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Progression-free survival (panel A) and overall survival (panel B) of the 27 patients enrolled in the CHRONOS trial. Keys: EOTTIME‚Äâ=‚ÄâEnd of Treatment Time; SURTIME‚Äâ=‚ÄâSurvival Time.</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec22-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec22">Supplementary information</h2><div class="c-article-section__content" id="Sec22-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Extended data figure captions and Supplementary Tables 1‚Äì3</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article‚Äôs Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article‚Äôs Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Circulating%20tumor%20DNA%20to%20guide%20rechallenge%20with%20panitumumab%20in%20metastatic%20colorectal%20cancer%3A%20the%20phase%202%20CHRONOS%20trial&amp;author=Andrea%20Sartore-Bianchi%20et%20al&amp;contentID=10.1038%2Fs41591-022-01886-0&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2022-08-01&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-022-01886-0" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-022-01886-0" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Sartore-Bianchi, A., Pietrantonio, F., Lonardi, S. <i>et al.</i> Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
                    <i>Nat Med</i> <b>28</b>, 1612‚Äì1618 (2022). https://doi.org/10.1038/s41591-022-01886-0</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01886-0?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-12-24">24 December 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-06-01">01 June 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-08-01">01 August 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-08">August 2022</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-022-01886-0</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/colorectal-cancer" data-track="click" data-track-action="view subject" data-track-label="link">Colorectal cancer</a></li><li class="c-article-subject-list__subject"><a href="/subjects/translational-research" data-track="click" data-track-action="view subject" data-track-label="link">Translational research</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:A scoping review of factors influencing the implementation of liquid biopsy for cancer care" href="https://doi.org/10.1186/s13046-025-03322-w">
                                        A scoping review of factors influencing the implementation of liquid biopsy for cancer care
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Samran Sheriff</li><li>Maree Saba</li><li>Louise Ann Ellis</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Journal of Experimental &amp; Clinical Cancer Research</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology" href="https://doi.org/10.1038/s41698-025-00876-y">
                                        Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Alexandra Bartolomucci</li><li>Monyse Nobrega</li><li>Julia V. Burnier</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>npj Precision Oncology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies" href="https://doi.org/10.1038/s41698-025-00892-y">
                                        Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Marwa Abdel Hamid</li><li>Lorenz M. Pammer</li><li>Andreas Seeber</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>npj Precision Oncology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Clinical utility and future perspectives of liquid biopsy in colorectal cancer" href="https://doi.org/10.1038/s43856-025-00852-4">
                                        Clinical utility and future perspectives of liquid biopsy in colorectal cancer
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Giorgio Patelli</li><li>Luca Lazzari</li><li>Silvia Marsoni</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Communications Medicine</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm" href="https://doi.org/10.1038/s41571-024-00965-0">
                                        Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Paolo Cirac√¨</li><li>Vittorio Studiale</li><li>Chiara Cremolini</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Reviews Clinical Oncology</i> (2025)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01886-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    
        <div class="c-article-associated-content__container">
            <section>
                <h2 class="c-article-associated-content__title u-mb-24">Associated content</h2>
                
                    
                        <div class="c-article-associated-content__collection collection u-mb-24">
                            <section>
                                <p class="c-article-associated-content__collection-label u-sans-serif u-text-bold u-mb-8">Collection</p>
                                <h3 class="c-article-associated-content__collection-title u-h3 u-mb-8">
                                    <a href="https://www.nature.com/collections/cbhjcefecb" class="u-link-inherit" data-track="click" data-track-action="view collection" data-track-category="associated content" data-track-label="collection" data-test="collection-link">Cancer research</a>
                                </h3>
                            </section>
                        </div>
                    
                    
                
            </section>
        </div>
        <script>
            window.dataLayer = window.dataLayer || [];
            window.dataLayer[0] = window.dataLayer[0] || {};
            window.dataLayer[0].content = window.dataLayer[0].content || {};
            window.dataLayer[0].content.associatedContentTypes = "collection";
            window.dataLayer[0].content.collections = "cbhjcefecb";
        </script>
    

    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: none;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec8" class="c-reading-companion__section-item"><a href="#Sec8" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec9" class="c-reading-companion__section-item"><a href="#Sec9" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-peer-review" class="c-reading-companion__section-item"><a href="#peer-review" data-track="click" data-track-action="section anchor" data-track-label="link:Peer review">Peer review</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec21" class="c-reading-companion__section-item"><a href="#Sec21" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec22" class="c-reading-companion__section-item"><a href="#Sec22" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-022-01886-0;doi=10.1038/s41591-022-01886-0;subjmeta=1504,1885,308,575,631,67,692;kwrd=Colorectal+cancer,Translational+research">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=469079748&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01886-0%26doi%3D10.1038/s41591-022-01886-0%26subjmeta%3D1504,1885,308,575,631,67,692%26kwrd%3DColorectal+cancer,Translational+research">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=469079748&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01886-0%26doi%3D10.1038/s41591-022-01886-0%26subjmeta%3D1504,1885,308,575,631,67,692%26kwrd%3DColorectal+cancer,Translational+research"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01886-0/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01886-0/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01886-0/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01886-0/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Extended Data Fig. 1 Schematic representation of the CHRONOS trial design (Amendment 3.0).</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig5_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig5_ESM.jpg" alt="extended data figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01886-0/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Extended Data Fig. 2 Molecular screening panel based on droplet-digital PCR implemented in the CHRONOS trial.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig6_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig6_ESM.jpg" alt="extended data figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01886-0/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 3 Outcome to panitumumab rechallenge in CHRONOS trial, according to (right) RECIST 1.1 response and progression-free survival and (left) the number and type of previous lines of treatments, type of previous anti-EGFR agent administered, and primary tumor sidedness.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01886-0/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 4 Progression-free survival (panel A) and overall survival (panel B) of the 27 patients enrolled in the CHRONOS trial.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01886-0/MediaObjects/41591_2022_1886_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01886-0/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J. Clin.</i> <b>71</b>, 209‚Äì249 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3322%2Fcaac.21660" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3322/caac.21660" data-track-item_id="10.3322/caac.21660">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33538338" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Global%20cancer%20statistics%202020%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;journal=CA%20Cancer%20J.%20Clin.&amp;doi=10.3322%2Fcaac.21660&amp;volume=71&amp;pages=209-249&amp;publication_year=2021&amp;author=Sung%2CH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Siegel, R. L., Miller, K. D., Fuchs, H. E. &amp; Jemal, A. Cancer statistics, 2021. <i>CA Cancer J. Clin.</i> <b>71</b>, 7‚Äì33 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3322%2Fcaac.21654" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3322/caac.21654" data-track-item_id="10.3322/caac.21654">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33433946" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Cancer%20statistics%2C%202021&amp;journal=CA%20Cancer%20J.%20Clin.&amp;doi=10.3322%2Fcaac.21654&amp;volume=71&amp;pages=7-33&amp;publication_year=2021&amp;author=Siegel%2CRL&amp;author=Miller%2CKD&amp;author=Fuchs%2CHE&amp;author=Jemal%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Di Nicolantonio, F. et al. Precision oncology in metastatic colorectal cancer‚Äîfrom biology to medicine. <i>Nat. Rev. Clin. Oncol.</i> <b>18</b>, 506‚Äì525 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41571-021-00495-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41571-021-00495-z" data-track-item_id="10.1038/s41571-021-00495-z">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33864051" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtlSjs7bE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Precision%20oncology%20in%20metastatic%20colorectal%20cancer%E2%80%94from%20biology%20to%20medicine&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-021-00495-z&amp;volume=18&amp;pages=506-525&amp;publication_year=2021&amp;author=Nicolantonio%2CF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Siravegna, G. &amp; Bardelli, A. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. <i>Mol. Oncol.</i> <b>10</b>, 475‚Äì480 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.molonc.2015.12.005" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.molonc.2015.12.005" data-track-item_id="10.1016/j.molonc.2015.12.005">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXitVGrt77E" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26774880" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Blood%20circulating%20tumor%20DNA%20for%20non-invasive%20genotyping%20of%20colon%20cancer%20patients&amp;journal=Mol.%20Oncol.&amp;doi=10.1016%2Fj.molonc.2015.12.005&amp;volume=10&amp;pages=475-480&amp;publication_year=2016&amp;author=Siravegna%2CG&amp;author=Bardelli%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Misale, S. et al. Emergence of <i>KRAS</i> mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> <b>486</b>, 532‚Äì536 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature11156" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature11156" data-track-item_id="10.1038/nature11156">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XpsVSrsb4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22722830" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927413" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Emergence%20of%20KRAS%20mutations%20and%20acquired%20resistance%20to%20anti-EGFR%20therapy%20in%20colorectal%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature11156&amp;volume=486&amp;pages=532-536&amp;publication_year=2012&amp;author=Misale%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. <i>Clin. Cancer Res</i> <b>21</b>, 2157‚Äì2166 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-14-2821" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-14-2821" data-track-item_id="10.1158/1078-0432.CCR-14-2821">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXnvFaqs7k%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25623215" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Emergence%20of%20multiple%20EGFR%20extracellular%20mutations%20during%20cetuximab%20treatment%20in%20colorectal%20cancer&amp;journal=Clin.%20Cancer%20Res&amp;doi=10.1158%2F1078-0432.CCR-14-2821&amp;volume=21&amp;pages=2157-2166&amp;publication_year=2015&amp;author=Arena%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Di Nicolantonio, F. et al. Wild-type <i>BRAF</i> is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <i>J. Clin. Oncol.</i> <b>26</b>, 5705‚Äì5712 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2008.18.0786" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2008.18.0786" data-track-item_id="10.1200/JCO.2008.18.0786">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19001320" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXotFemsA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Wild-type%20BRAF%20is%20required%20for%20response%20to%20panitumumab%20or%20cetuximab%20in%20metastatic%20colorectal%20cancer&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2008.18.0786&amp;volume=26&amp;pages=5705-5712&amp;publication_year=2008&amp;author=Nicolantonio%2CF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Montagut, C. et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA Analyses: a phase 2 randomized clinical trial. <i>JAMA Oncol.</i> <b>4</b>, e175245 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1001%2Fjamaoncol.2017.5245" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1001/jamaoncol.2017.5245" data-track-item_id="10.1001/jamaoncol.2017.5245">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29423521" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885274" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20Sym004%20in%20patients%20with%20metastatic%20colorectal%20cancer%20with%20acquired%20resistance%20to%20anti-EGFR%20therapy%20and%20molecularly%20selected%20by%20circulating%20tumor%20DNA%20Analyses%3A%20a%20phase%202%20randomized%20clinical%20trial&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2017.5245&amp;volume=4&amp;publication_year=2018&amp;author=Montagut%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nat. Med.</i> <b>21</b>, 795‚Äì801 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnm.3870" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nm.3870" data-track-item_id="10.1038/nm.3870">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFeisrrI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26030179" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868598" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clonal%20evolution%20and%20resistance%20to%20EGFR%20blockade%20in%20the%20blood%20of%20colorectal%20cancer%20patients&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm.3870&amp;volume=21&amp;pages=795-801&amp;publication_year=2015&amp;author=Siravegna%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Morelli, M. P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. <i>Ann. Oncol.</i> <b>26</b>, 731‚Äì736 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdv005" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdv005" data-track-item_id="10.1093/annonc/mdv005">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC2MrgsVyltQ%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25628445" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374387" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Characterizing%20the%20patterns%20of%20clonal%20selection%20in%20circulating%20tumor%20DNA%20from%20patients%20with%20colorectal%20cancer%20refractory%20to%20anti-EGFR%20treatment&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdv005&amp;volume=26&amp;pages=731-736&amp;publication_year=2015&amp;author=Morelli%2CMP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Ann. Oncol.</i> <b>30</b>, 243‚Äì249 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdy509" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdy509" data-track-item_id="10.1093/annonc/mdy509">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3crjtlOmuw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30462160" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Anti-EGFR-resistant%20clones%20decay%20exponentially%20after%20progression%3A%20implications%20for%20anti-EGFR%20re-challenge&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdy509&amp;volume=30&amp;pages=243-249&amp;publication_year=2019&amp;author=Parseghian%2CCM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Ann. Oncol.</i> <b>29</b>, 119‚Äì126 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdx504" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdx504" data-track-item_id="10.1093/annonc/mdx504">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC1M%2FitV2ltg%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28945848" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Dynamic%20molecular%20analysis%20and%20clinical%20correlates%20of%20tumor%20evolution%20within%20a%20phase%20II%20trial%20of%20panitumumab-based%20therapy%20in%20metastatic%20colorectal%20cancer&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx504&amp;volume=29&amp;pages=119-126&amp;publication_year=2018&amp;author=Siena%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Siravegna, G., Marsoni, S., Siena, S. &amp; Bardelli, A. Integrating liquid biopsies into the management of cancer. <i>Nat. Rev. Clin. Oncol.</i> <b>14</b>, 531‚Äì548 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnrclinonc.2017.14" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nrclinonc.2017.14" data-track-item_id="10.1038/nrclinonc.2017.14">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXkvVSns7g%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28252003" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Integrating%20liquid%20biopsies%20into%20the%20management%20of%20cancer&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fnrclinonc.2017.14&amp;volume=14&amp;pages=531-548&amp;publication_year=2017&amp;author=Siravegna%2CG&amp;author=Marsoni%2CS&amp;author=Siena%2CS&amp;author=Bardelli%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>N. Engl. J. Med.</i> <b>372</b>, 1909‚Äì1919 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1414325" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1414325" data-track-item_id="10.1056/NEJMoa1414325">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25970050" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%20trial%20of%20TAS-102%20for%20refractory%20metastatic%20colorectal%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1414325&amp;volume=372&amp;pages=1909-1919&amp;publication_year=2015&amp;author=Mayer%2CRJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> <b>381</b>, 303‚Äì312 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0140-6736%2812%2961900-X" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0140-6736(12)61900-X" data-track-item_id="10.1016/S0140-6736(12)61900-X">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xhslarsr%2FE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23177514" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Regorafenib%20monotherapy%20for%20previously%20treated%20metastatic%20colorectal%20cancer%20%28CORRECT%29%3A%20an%20international%2C%20multicentre%2C%20randomised%2C%20placebo-controlled%2C%20phase%203%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2812%2961900-X&amp;volume=381&amp;pages=303-312&amp;publication_year=2013&amp;author=Grothey%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Siena, S., Marsoni, S. &amp; Sartore-Bianchi, A. Breaking barriers in HER2<sup>+</sup> cancers. <i>Cancer Cell</i> <b>38</b>, 317‚Äì319 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ccell.2020.07.012" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ccell.2020.07.012" data-track-item_id="10.1016/j.ccell.2020.07.012">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhslWqt7fJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32857948" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Breaking%20barriers%20in%20HER2%2B%20cancers&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2020.07.012&amp;volume=38&amp;pages=317-319&amp;publication_year=2020&amp;author=Siena%2CS&amp;author=Marsoni%2CS&amp;author=Sartore-Bianchi%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Amatu, A. et al. Tropomyosin receptor kinase (TRK) biology and the role of <i>NTRK</i> gene fusions in cancer. <i>Ann. Oncol.</i> <b>30</b>, viii5‚Äìviii15 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdz383" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdz383" data-track-item_id="10.1093/annonc/mdz383">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3MfgtlShsA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32223939" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859819" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tropomyosin%20receptor%20kinase%20%28TRK%29%20biology%20and%20the%20role%20of%20NTRK%20gene%20fusions%20in%20cancer&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdz383&amp;volume=30&amp;pages=viii5-viii15&amp;publication_year=2019&amp;author=Amatu%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>J. Natl Compr. Cancer Netw.</i> <b>19</b>, 329‚Äì359 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.6004%2Fjnccn.2021.0012" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.6004/jnccn.2021.0012" data-track-item_id="10.6004/jnccn.2021.0012">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Colon%20Cancer%2C%20Version%202.2021%2C%20NCCN%20Clinical%20Practice%20Guidelines%20in%20Oncology&amp;journal=J.%20Natl%20Compr.%20Cancer%20Netw.&amp;doi=10.6004%2Fjnccn.2021.0012&amp;volume=19&amp;pages=329-359&amp;publication_year=2021&amp;author=Benson%2CAB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Yoshino, T. et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Ann. Oncol.</i> <b>29</b>, 44‚Äì70 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdx738" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdx738" data-track-item_id="10.1093/annonc/mdx738">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC1M3jtVanug%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29155929" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pan-Asian%20adapted%20ESMO%20consensus%20guidelines%20for%20the%20management%20of%20patients%20with%20metastatic%20colorectal%20cancer%3A%20a%20JSMO-ESMO%20initiative%20endorsed%20by%20CSCO%2C%20KACO%2C%20MOS%2C%20SSO%20and%20TOS&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx738&amp;volume=29&amp;pages=44-70&amp;publication_year=2018&amp;author=Yoshino%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Mauri, G. et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. <i>Cancer Treat. Rev.</i> <b>73</b>, 41‚Äì53 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ctrv.2018.12.006" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ctrv.2018.12.006" data-track-item_id="10.1016/j.ctrv.2018.12.006">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXkvVGlsA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30616224" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Retreatment%20with%20anti-EGFR%20monoclonal%20antibodies%20in%20metastatic%20colorectal%20cancer%3A%20systematic%20review%20of%20different%20strategies&amp;journal=Cancer%20Treat.%20Rev.&amp;doi=10.1016%2Fj.ctrv.2018.12.006&amp;volume=73&amp;pages=41-53&amp;publication_year=2019&amp;author=Mauri%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Mauri, G. et al. Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities. <i>Cancer Treat. Rev.</i> <b>91</b>, 102112 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ctrv.2020.102112" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ctrv.2020.102112" data-track-item_id="10.1016/j.ctrv.2020.102112">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitFyisbvI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33091698" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Oxaliplatin%20retreatment%20in%20metastatic%20colorectal%20cancer%3A%20systematic%20review%20and%20future%20research%20opportunities&amp;journal=Cancer%20Treat.%20Rev.&amp;doi=10.1016%2Fj.ctrv.2020.102112&amp;volume=91&amp;publication_year=2020&amp;author=Mauri%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Cremolini, C. et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial.<i>JAMA Oncol.</i> <b>5</b>, 343‚Äì350 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1001%2Fjamaoncol.2018.5080" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1001/jamaoncol.2018.5080" data-track-item_id="10.1001/jamaoncol.2018.5080">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30476968" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Rechallenge%20for%20patients%20With%20RAS%20and%20BRAF%20wild-type%20metastatic%20colorectal%20cancer%20with%20acquired%20resistance%20to%20first-line%20cetuximab%20and%20irinotecan%3A%20a%20phase%202%20single-arm%20clinical%20trial.&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2018.5080&amp;volume=5&amp;pages=343-350&amp;publication_year=2019&amp;author=Cremolini%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Martinelli, E. et al. Cetuximab rechallenge plus avelumab in pretreated patients with <i>RAS</i> wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. <i>JAMA Oncol.</i> <b>7</b>, 1529‚Äì1535 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1001%2Fjamaoncol.2021.2915" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1001/jamaoncol.2021.2915" data-track-item_id="10.1001/jamaoncol.2021.2915">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34382998" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Cetuximab%20rechallenge%20plus%20avelumab%20in%20pretreated%20patients%20with%20RAS%20wild-type%20metastatic%20colorectal%20cancer%3A%20the%20phase%202%20single-arm%20clinical%20CAVE%20trial&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2021.2915&amp;volume=7&amp;pages=1529-1535&amp;publication_year=2021&amp;author=Martinelli%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Alix-Panabi√®res, C. The future of liquid biopsy. <i>Nature</i> <b>579</b>, S9 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fd41586-020-00844-5" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/d41586-020-00844-5" data-track-item_id="10.1038/d41586-020-00844-5">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32214259" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXlslKmsbs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20future%20of%20liquid%20biopsy&amp;journal=Nature&amp;doi=10.1038%2Fd41586-020-00844-5&amp;volume=579&amp;publication_year=2020&amp;author=Alix-Panabi%C3%A8res%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <i>Eur. J. Cancer</i> <b>45</b>, 228‚Äì247 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ejca.2008.10.026" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ejca.2008.10.026" data-track-item_id="10.1016/j.ejca.2008.10.026">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19097774" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=New%20response%20evaluation%20criteria%20in%20solid%20tumours%3A%20revised%20RECIST%20guideline%20%28version%201.1%29&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;volume=45&amp;pages=228-247&amp;publication_year=2009&amp;author=Eisenhauer%2CEA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Ali, M. et al. Codon bias imposes a targetable limitation on <i>KRAS</i>-driven therapeutic resistance. <i>Nat. Commun.</i> <b>8</b>, 15617 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fncomms15617" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ncomms15617" data-track-item_id="10.1038/ncomms15617">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28593995" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472712" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Codon%20bias%20imposes%20a%20targetable%20limitation%20on%20KRAS-driven%20therapeutic%20resistance&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms15617&amp;volume=8&amp;publication_year=2017&amp;author=Ali%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Modest, D. P., Pant, S. &amp; Sartore-Bianchi, A. Treatment sequencing in metastatic colorectal cancer. <i>Eur. J. Cancer</i><b>109</b>, 70‚Äì83 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ejca.2018.12.019" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ejca.2018.12.019" data-track-item_id="10.1016/j.ejca.2018.12.019">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVaqu78%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30690295" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Treatment%20sequencing%20in%20metastatic%20colorectal%20cancer&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2018.12.019&amp;volume=109&amp;pages=70-83&amp;publication_year=2019&amp;author=Modest%2CDP&amp;author=Pant%2CS&amp;author=Sartore-Bianchi%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">Bertotti, A. et al. The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> <b>526</b>, 263‚Äì267 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature14969" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature14969" data-track-item_id="10.1038/nature14969">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhs1Chu7jE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26416732" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878148" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20genomic%20landscape%20of%20response%20to%20EGFR%20blockade%20in%20colorectal%20cancer&amp;journal=Nature&amp;doi=10.1038%2Fnature14969&amp;volume=526&amp;pages=263-267&amp;publication_year=2015&amp;author=Bertotti%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Sartore-Bianchi, A. et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. <i>Oncologist</i> <b>24</b>, 1395‚Äì1402 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1634%2Ftheoncologist.2018-0785" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1634/theoncologist.2018-0785" data-track-item_id="10.1634/theoncologist.2018-0785">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXkvVCrsLc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30952821" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795149" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=HER2%20positivity%20predicts%20unresponsiveness%20to%20EGFR-targeted%20treatment%20in%20metastatic%20colorectal%20cancer&amp;journal=Oncologist&amp;doi=10.1634%2Ftheoncologist.2018-0785&amp;volume=24&amp;pages=1395-1402&amp;publication_year=2019&amp;author=Sartore-Bianchi%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Argiles, G., Arnold, D., Prager, G., Sobrero, A. F. &amp; Van Cutsem, E. Maximising clinical benefit with adequate patient management beyond the second line in mCRC. <i>ESMO Open</i> <b>4</b>, e000495 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1136%2Fesmoopen-2019-000495" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1136/esmoopen-2019-000495" data-track-item_id="10.1136/esmoopen-2019-000495">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31231561" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555611" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Maximising%20clinical%20benefit%20with%20adequate%20patient%20management%20beyond%20the%20second%20line%20in%20mCRC&amp;journal=ESMO%20Open&amp;doi=10.1136%2Fesmoopen-2019-000495&amp;volume=4&amp;publication_year=2019&amp;author=Argiles%2CG&amp;author=Arnold%2CD&amp;author=Prager%2CG&amp;author=Sobrero%2CAF&amp;author=Cutsem%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Rossini, D. et al. Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis. <i>Clin. Colorectal Cancer</i> <b>19</b>, 191‚Äì199 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.clcc.2020.03.009" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.clcc.2020.03.009" data-track-item_id="10.1016/j.clcc.2020.03.009">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32466976" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Retreatment%20with%20anti-EGFR%20antibodies%20in%20metastatic%20colorectal%20cancer%20patients%3A%20a%20multi-institutional%20analysis&amp;journal=Clin.%20Colorectal%20Cancer&amp;doi=10.1016%2Fj.clcc.2020.03.009&amp;volume=19&amp;pages=191-199&amp;publication_year=2020&amp;author=Rossini%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Khan, K. H. et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. <i>Cancer Discov.</i> <b>8</b>, 1270‚Äì1285 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-17-0891" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-17-0891" data-track-item_id="10.1158/2159-8290.CD-17-0891">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXmt1ehsbg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30166348" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380469" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Longitudinal%20liquid%20biopsy%20and%20mathematical%20modeling%20of%20clonal%20evolution%20forecast%20time%20to%20treatment%20failure%20in%20the%20PROSPECT-C%20phase%20II%20colorectal%20cancer%20clinical%20trial&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-17-0891&amp;volume=8&amp;pages=1270-1285&amp;publication_year=2018&amp;author=Khan%2CKH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Thierry, A. R. et al. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. <i>Clin. Cancer Res.</i> <b>23</b>, 4578‚Äì4591 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-17-0232" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-17-0232" data-track-item_id="10.1158/1078-0432.CCR-17-0232">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlCmu7vJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28400427" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562356" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Circulating%20DNA%20demonstrates%20convergent%20evolution%20and%20common%20resistance%20mechanisms%20during%20treatment%20of%20colorectal%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-17-0232&amp;volume=23&amp;pages=4578-4591&amp;publication_year=2017&amp;author=Thierry%2CAR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Sartore-Bianchi, A. et al. <i>PIK3CA</i> mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. <i>Cancer Res.</i> <b>69</b>, 1851‚Äì1857 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F0008-5472.CAN-08-2466" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/0008-5472.CAN-08-2466" data-track-item_id="10.1158/0008-5472.CAN-08-2466">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXisFSrt7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19223544" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PIK3CA%20mutations%20in%20colorectal%20cancer%20are%20associated%20with%20clinical%20resistance%20to%20EGFR-targeted%20monoclonal%20antibodies&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-08-2466&amp;volume=69&amp;pages=1851-1857&amp;publication_year=2009&amp;author=Sartore-Bianchi%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Cremolini, C. et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case‚Äìcontrol study. <i>Ann. Oncol.</i> <b>28</b>, 3009‚Äì3014 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdx546" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdx546" data-track-item_id="10.1093/annonc/mdx546">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC1M7itVCgtQ%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29045518" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Negative%20hyper-selection%20of%20metastatic%20colorectal%20cancer%20patients%20for%20anti-EGFR%20monoclonal%20antibodies%3A%20the%20PRESSING%20case%E2%80%93control%20study&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx546&amp;volume=28&amp;pages=3009-3014&amp;publication_year=2017&amp;author=Cremolini%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Bardelli, A. et al. Amplification of the <i>MET</i> receptor drives resistance to anti-EGFR therapies in colorectal cancer. <i>Cancer Discov.</i> <b>3</b>, 658‚Äì673 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-12-0558" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-12-0558" data-track-item_id="10.1158/2159-8290.CD-12-0558">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXptVOrt7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23729478" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078408" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Amplification%20of%20the%20MET%20receptor%20drives%20resistance%20to%20anti-EGFR%20therapies%20in%20colorectal%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-12-0558&amp;volume=3&amp;pages=658-673&amp;publication_year=2013&amp;author=Bardelli%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nat. Med.</i> <b>25</b>, 1415‚Äì1421 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-019-0561-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-019-0561-9" data-track-item_id="10.1038/s41591-019-0561-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhslelurnJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31501609" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741444" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Liquid%20versus%20tissue%20biopsy%20for%20detecting%20acquired%20resistance%20and%20tumor%20heterogeneity%20in%20gastrointestinal%20cancers&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-019-0561-9&amp;volume=25&amp;pages=1415-1421&amp;publication_year=2019&amp;author=Parikh%2CAR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Russo, M. et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. <i>Cancer Discov.</i> <b>6</b>, 147‚Äì153 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-15-1283" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-15-1283" data-track-item_id="10.1158/2159-8290.CD-15-1283">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XisVyjtL4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26644315" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20heterogeneity%20and%20lesion-specific%20response%20to%20targeted%20therapy%20in%20colorectal%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-15-1283&amp;volume=6&amp;pages=147-153&amp;publication_year=2016&amp;author=Russo%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Siena, S. et al. Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). <i>Ann. Oncol.</i> <b>32</b>, S530‚ÄìS582 (2021).</p><p class="c-reading-companion__reference-links"><a href="http://scholar.google.com/scholar_lookup?&amp;title=Exploratory%20biomarker%20analysis%20of%20DESTINY-CRC01%2C%20a%20phase%20II%2C%20multicenter%2C%20open-label%20study%20of%20trastuzumab%20deruxtecan%20%28T-DXd%2C%20DS-8201%29%20in%20patients%20%28pts%29%20with%20HER2-expressing%20metastatic%20colorectal%20cancer%20%28mCRC%29&amp;journal=Ann.%20Oncol.&amp;volume=32&amp;publication_year=2021&amp;author=Siena%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Downing, A. et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. <i>Gut</i> <b>66</b>, 89‚Äì96 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1136%2Fgutjnl-2015-311308" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1136/gutjnl-2015-311308" data-track-item_id="10.1136/gutjnl-2015-311308">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27797935" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=High%20hospital%20research%20participation%20and%20improved%20colorectal%20cancer%20survival%20outcomes%3A%20a%20population-based%20study&amp;journal=Gut&amp;doi=10.1136%2Fgutjnl-2015-311308&amp;volume=66&amp;pages=89-96&amp;publication_year=2017&amp;author=Downing%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Ignatiadis, M., Sledge, G. W. &amp; Jeffrey, S. S. Liquid biopsy enters the clinic‚Äîimplementation issues and future challenges. <i>Nat. Rev. Clin. Oncol.</i> <b>18</b>, 297‚Äì312 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41571-020-00457-x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41571-020-00457-x" data-track-item_id="10.1038/s41571-020-00457-x">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33473219" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Liquid%20biopsy%20enters%20the%20clinic%E2%80%94implementation%20issues%20and%20future%20challenges&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-020-00457-x&amp;volume=18&amp;pages=297-312&amp;publication_year=2021&amp;author=Ignatiadis%2CM&amp;author=Sledge%2CGW&amp;author=Jeffrey%2CSS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Moretto, R. et al. Rationale and study design of the PARERE trial: randomized phase ii study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients. <i>Clin. Colorectal Cancer</i> <b>20</b>, 314‚Äì317 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.clcc.2021.07.001" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.clcc.2021.07.001" data-track-item_id="10.1016/j.clcc.2021.07.001">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34364814" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Rationale%20and%20study%20design%20of%20the%20PARERE%20trial%3A%20randomized%20phase%20ii%20study%20of%20panitumumab%20re-treatment%20followed%20by%20regorafenib%20versus%20the%20reverse%20sequence%20in%20RAS%20and%20BRAF%20wild-type%20chemo-refractory%20metastatic%20colorectal%20cancer%20patients&amp;journal=Clin.%20Colorectal%20Cancer&amp;doi=10.1016%2Fj.clcc.2021.07.001&amp;volume=20&amp;pages=314-317&amp;publication_year=2021&amp;author=Moretto%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Strickler, J. H. et al. PULSE: a randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with <i>RAS</i> wild-type metastatic colorectal cancer (mCRC). <i>J. Clin. Oncol.</i> <a href="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143">https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS143</a> (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. <i>JAMA</i> <b>310</b>, 2191‚Äì2194 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1001%2Fjama.2013.281053" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1001/jama.2013.281053" data-track-item_id="10.1001/jama.2013.281053">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXmtVOmsA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=World%20Medical%20Association%20Declaration%20of%20Helsinki%3A%20ethical%20principles%20for%20medical%20research%20involving%20human%20subjects&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2013.281053&amp;volume=310&amp;pages=2191-2194&amp;publication_year=2013" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. <i>Anal. Chem.</i> <b>83</b>, 8604‚Äì8610 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1021%2Fac202028g" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1021/ac202028g" data-track-item_id="10.1021/ac202028g">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXhtlyhtLzL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22035192" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216358" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=High-throughput%20droplet%20digital%20PCR%20system%20for%20absolute%20quantitation%20of%20DNA%20copy%20number&amp;journal=Anal.%20Chem.&amp;doi=10.1021%2Fac202028g&amp;volume=83&amp;pages=8604-8610&amp;publication_year=2011&amp;author=Hindson%2CBJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. <i>Nat. Protoc.</i> <b>9</b>, 2586‚Äì2606 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnprot.2014.170" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nprot.2014.170" data-track-item_id="10.1038/nprot.2014.170">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhslaqs7jF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25299156" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271547" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Detecting%20ultralow-frequency%20mutations%20by%20Duplex%20Sequencing&amp;journal=Nat.%20Protoc.&amp;doi=10.1038%2Fnprot.2014.170&amp;volume=9&amp;pages=2586-2606&amp;publication_year=2014&amp;author=Kennedy%2CSR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR47">Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. <i>Proc. Natl Acad. Sci. USA</i> <b>109</b>, 14508‚Äì14513 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1073%2Fpnas.1208715109" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1073/pnas.1208715109" data-track-item_id="10.1073/pnas.1208715109">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhsVaqu77E" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22853953" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437896" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Detection%20of%20ultra-rare%20mutations%20by%20next-generation%20sequencing&amp;journal=Proc.%20Natl%20Acad.%20Sci.%20USA&amp;doi=10.1073%2Fpnas.1208715109&amp;volume=109&amp;pages=14508-14513&amp;publication_year=2012&amp;author=Schmitt%2CMW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR48">Corti, G. et al. A genomic analysis workflow for colorectal cancer precision oncology. <i>Clin. Colorectal Cancer</i> <b>18</b>, 91‚Äì101 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.clcc.2019.02.008" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.clcc.2019.02.008" data-track-item_id="10.1016/j.clcc.2019.02.008">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30981604" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20genomic%20analysis%20workflow%20for%20colorectal%20cancer%20precision%20oncology&amp;journal=Clin.%20Colorectal%20Cancer&amp;doi=10.1016%2Fj.clcc.2019.02.008&amp;volume=18&amp;pages=91-101&amp;publication_year=2019&amp;author=Corti%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR49">Crisafulli, G. et al. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> <b>4</b>, e000572 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1136%2Fesmoopen-2019-000572" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1136/esmoopen-2019-000572" data-track-item_id="10.1136/esmoopen-2019-000572">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32149725" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001107" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Whole%20exome%20sequencing%20analysis%20of%20urine%20trans-renal%20tumour%20DNA%20in%20metastatic%20colorectal%20cancer%20patients&amp;journal=ESMO%20Open&amp;doi=10.1136%2Fesmoopen-2019-000572&amp;volume=4&amp;publication_year=2019&amp;author=Crisafulli%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">¬© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    


    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif c-site-messages--nature-briefing-transres" data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: TranslationalResearch">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: TranslationalResearch">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing: Translational Research" src="/static/images/logos/nature-briefing-logo-transres-white-1245a3c374.svg" width="213" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing: Translational Research</em> newsletter ‚Äî top stories in biotechnology, drug discovery and pharma.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/translational_research" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: TranslationalResearch">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="TransResBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="TransResBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:translational_research" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: TranslationalResearch">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get what matters in translational research, free to your inbox weekly.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="/briefing/translational-research/?brieferEntryPoint=TransResBriefingBanner">Sign up for Nature Briefing: Translational Research
            </a>
        </div>

    </div>

</div>

    




<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-022-01886-0&amp;format=js&amp;last_modified=2022-08-01" async=""></script>

<vzx-vckzjqqarvvd></vzx-vckzjqqarvvd><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>